Sweroside: unveiling broad therapeutic potential—from mechanistic insights to clinical potential

Abstract

Background:

Sweroside, a secoiridoid glycoside abundantly present in medicinal plants, has garnered significant attention due to its diverse bioactivities, including anti-inflammatory, antioxidant, hepatoprotective, antidiabetic, antibacterial, and anticancer effects. Additionally, it exhibits promising potential in neuroprotection and dermatological health.

Purpose:

This review aims to provide a comprehensive analysis of Sweroside, focusing on its sources, biosynthetic pathways, pharmacodynamic mechanisms, and therapeutic potential. The insights presented aim to facilitate the development of novel pharmacotherapies and advance precision medicine.

Methods:

A systematic review of the literature was conducted using databases such as PubMed, Web of Science, and Google Scholar. The study examined Sweroside’s sources, distribution, biosynthesis, pharmacodynamics, and therapeutic applications. Challenges in its clinical translation were also evaluated, with proposed strategies to enhance bioavailability.

Results:

Sweroside modulates critical signaling pathways, such as NF-κB, mTOR, MAPK, and PI3K/Akt, and their molecular substrates, contributing to its therapeutic effects across various pathological conditions. Preclinical studies demonstrate its efficacy in treating hepatic disorders, osteoporosis, cardiovascular diseases, and neurological dysfunctions. It also shows promise in neuroprotection and dermatological health. However, clinical translation is hindered by its low bioavailability and rapid metabolic degradation.

Conclusion:

Sweroside is a versatile natural metabolite with multi-target therapeutic potential, positioning it as a promising candidate for next-generation pharmacotherapies. To realize its clinical potential, future research should prioritize optimizing its pharmacokinetics, including enhancing bioavailability and developing advanced drug delivery systems. Further investigation into its molecular mechanisms and intracellular targets across diverse pathological conditions is essential. Sweroside’s integration into precision medicine offers significant opportunities for addressing chronic and complex diseases.

Graphical Abstract

1 Introduction

Natural products, organic compounds derived from organisms in nature, occupy a pivotal role in drug discovery due to their unique biological activities and multifunctional therapeutic potential. In recent years, natural products sourced from medicinal plants have garnered significant attention in scientific research, primarily owing to their exceptional pharmacological properties and relatively low toxicity. Among these, iridoid glycosides (Fadzil et al., 2021) have emerged as a prominent class of bioactive metabolites, with Sweroside standing out as a typical representative.

Sweroside, first isolated from Swertia chirayita, is widely distributed among Gentianaceae plants, particularly in the Qinghai-Tibet Plateau and the source region of the Yellow River (Zhou D. et al., 2021). In traditional medicine, Swertia chirayita—referred to as “Dida” or “Zangyinchen” in Tibet, Yunnan, and Guizhou provinces of China—has long been revered for its potent anti-hepatitis, antipyretic, and detoxifying properties (Wang et al., 2013). Beyond Swertia chirayita, other species within the Swertia genus also exhibit a broad spectrum of pharmacological activities, including anticancer, antidiabetic, antibacterial, antioxidant, and neuroprotective effects. These diverse therapeutic applications underscore the likelihood that Sweroside serves as a key bioactive metabolite underpinning the efficacy of these traditional remedies.

Extensive research has further highlighted Sweroside’s remarkable pharmacological profile, encompassing anti-inflammatory, antioxidant, analgesic, and neuroprotective effects. Notably, it demonstrates significant therapeutic potential in addressing a range of major diseases, including liver disorders, osteoporosis, cancer, rheumatoid arthritis, diabetic nephropathy, myocardial injury, and Alzheimer’s disease (Yang et al., 2022). These multifaceted properties have positioned Sweroside as a focal point in the development of novel therapeutic strategies. However, its successful clinical translation necessitates a deeper understanding of its intricate molecular mechanisms and diverse biological targets. Mechanistically, Sweroside’s antioxidant and anti-inflammatory properties are particularly noteworthy, offering critical insights into its therapeutic potential. Studies have revealed that Sweroside effectively attenuates inflammatory responses by suppressing the release of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6, and IL-8) through inhibition of the NF-κB/NLRP3 signaling pathway. Furthermore, it promotes osteoblast differentiation by modulating key molecules associated with cellular proliferation and differentiation, such as phosphorylated mammalian target of rapamycin (P-mTOR), phosphorylated S6 protein (PS6), Runt-related transcription factor 2 (RUNX2), and Osterix (OSX). These findings provide robust theoretical support for its potential application in treating bone metabolism disorders. Additionally, Sweroside exerts precise control over apoptosis by regulating apoptosis-related proteins, including Bcl-2 and Bax, further highlighting its multidimensional biological effects. Collectively, these mechanisms establish a solid scientific foundation for the application of Sweroside in combating chronic diseases.

Despite significant advancements in understanding the pharmacological activities and mechanisms of Sweroside, current research remains fragmented and lacks systematic integration. This review seeks to address this gap by providing a comprehensive synthesis of Sweroside’s distribution in plants, biosynthetic pathways, clinical applications, molecular mechanisms, and recent progress in metabolism and toxicology. By consolidating current insights, this review aims to construct a clearer scientific framework for Sweroside as a promising natural therapeutic agent and to lay a robust theoretical foundation for its future academic exploration and clinical development.

2 Methods

2.1 Search strategy

We comprehensively searched databases including PubMed, Web of Science, Elsevier ScienceDirect, and Google Scholar. The main search terms used were “Sweroside”, “anti-inflammatory”, “biosynthesis”, “toxicology”, and “therapeutic”, which were combined using Boolean operators (AND/OR). The search covered all published articles. The titles and abstracts of the retrieved articles were then reviewed.

2.2 Selection criteria

Inclusion criteria: Studies on biosynthetic precursors and gene regulation of Sweroside; Research involving in vivo or in vitro metabolism of Sweroside; Original studies providing experimental data, with clear experimental methods, reasonable control groups, and reliable data.

Exclusion criteria: Studies irrelevant to Sweroside; Studies without experimental verification; Review articles.

2.3 Data analysis

This review comprehensively analyzed data related to the pharmacokinetics, biological activities, therapeutic effects, and toxicity of Sweroside. This included improvements in various diseases by Sweroside in different cell and animal models, its effects on inflammation mediators and oxidative stress markers associated with various diseases, as well as the drug’s metabolic profile.

2.4 Search results

A total of 4,450 articles related to Sweroside were found in Google Scholar, 747 in Elsevier ScienceDirect, 273 in Web of Science, and 281 in PubMed. After screening according to the inclusion and exclusion criteria, 31 articles were finally selected.

3 The plant sources and related biosynthetic pathways of swroside

Sweroside, a secoiridoid metabolite predominantly derived from plants of the Gentianaceae family, is most abundantly found in species of the genus Swertia. For centuries, Swertia plants have been integral to traditional medicine, celebrated for their heat-clearing and detoxifying properties. Their therapeutic applications are well-documented in various traditional medical systems, including the Indian Pharmacopoeia, British herbal medicine, Ayurveda, Unani, and Siddha (Kumar and Van Staden, 2016). These systems have employed Swertia plants to treat a wide array of ailments, such as malaria, liver diseases, jaundice, cholecystitis, pneumonia, and diabetes (Kshirsagar et al., 2019). In Tibetan and Yunnan regions of China, Swertia plants—referred to as “Dida” or “Zangyinchen”—are cornerstone components of Tibetan traditional medicine, particularly renowned for their efficacy in treating liver and gallbladder disorders. Globally, approximately 170 species of Swertia have been identified, with the majority distributed across Asia and smaller populations found in the Americas and Africa. The Tibetan Plateau in Southwest China serves as a biodiversity hotspot for this genus, hosting approximately 79 species, of which nearly 40 possess confirmed medicinal value (Tong et al., 2015). Similarly, India has recorded around 40 species of Swertia. Beyond the Swertia genus, Sweroside has also been isolated from other medicinal plants, including Lonicera (Kumar et al., 2000; Liang et al., 2013a), Cornus officinalis Sieb. et Zucc. (Huang et al., 2018), and Gentiana macrophylla Pall. (Liang et al., 2013b). This extensive diversity of plant resources, coupled with their wide geographical distribution, provides a robust foundation for the exploration and application of Sweroside in pharmacological research.

Chemically, Sweroside is an odorless, bitter-tasting powder characterized by its high stability (Jovanovic et al., 2021), making it a promising candidate for applications in the pharmaceutical and food industries. Modern pharmacological studies have revealed its multifaceted bioactivities, including anti-inflammatory, antioxidant, analgesic, hepatoprotective, antidiabetic, and antimicrobial effects. For instance, Sweroside has been shown to exert significant anti-inflammatory effects by downregulating the expression of pro-inflammatory cytokines through inhibition of the NF-κB/NLRP3 signaling pathway. Furthermore, it has demonstrated potential in the treatment of diabetes, neurodegenerative diseases, and certain toxicological conditions (Deng et al., 2013). These discoveries not only validate the traditional medicinal applications of Sweroside but also establish a robust scientific foundation for its exploration in novel therapeutic domains.

In recent years, derivatives of Sweroside have garnered attention for their expanded pharmacological potential, including anti-inflammatory, anticancer, and neuroregenerative properties. For example, a derivative with potent anti-inflammatory effects has been isolated from Gentiana scabra (He et al., 2015). Additionally, chemically synthesized Sweroside derivatives containing diindolylmethane structures have shown efficacy in inhibiting the proliferation of specific cancer cells. Notably, these derivatives, when combined with paclitaxel, significantly reverse drug resistance, highlighting their potential in overcoming therapeutic challenges (Pan, 2023). Collectively, these advancements not only broaden the application spectrum of Sweroside and its derivatives but also underscore their promise as candidates for further development in anti-inflammatory and anticancer therapies.

3.1 Sweroside: botanical sources

Sweroside is predominantly found in plants of the Gentianaceae family, particularly within the genus Gentiana, and in species of the Cornaceae family, notably the genus Cornus. These plants have captured considerable scientific interest due to their pronounced hepatoprotective, antitumor, and anti-inflammatory activities, alongside a range of other biological properties. Furthermore, Sweroside’s occurrence in additional medicinal plants has broadened its potential for research and therapeutic applications. Understanding the distribution patterns of Sweroside holds significant importance for advancing the development and sustainable utilization of medicinal plant resources. This review systematically examines its distribution across various plant species (Table 1).

3.2 Biosynthetic pathways and regulatory mechanisms of Sweroside

Although the biosynthetic mechanism of Sweroside remains incompletely understood, current research has uncovered critical pathways and regulatory networks, offering valuable insights into its metabolic processes. In plants of the Gentianaceae family, the biosynthetic pathway of secoiridoids involves the sequential transformation of loganic acid into Sweroside, followed by its conversion into gentiopicroside through the intermediary swertiamarin (Li et al., 2018). This pathway was further corroborated by the work of Tovilovic-Kovacevic and colleagues (Tovilovic-Kovacevic et al., 2020), whose findings not only elucidated the metabolic route of Sweroside but also provided a theoretical framework for studying its intricate transformation and accumulation mechanisms within plant systems.

The biosynthesis of terpenoid metabolites fundamentally relies on two primary metabolic pathways: mevalonate pathway (MVA) and the methylerythritol phosphate pathway (MEP, also known as 1-deoxy-D-xylulose-5-phosphate pathway, DXP) pathway. These pathways converge within the metabolic network, jointly facilitating the synthesis of isoprenoid diphosphate (IPP) and dimethylallyl diphosphate (DMAPP)—essential precursors for cyclic terpenoid biosynthesis. Notably, in Sweroside biosynthesis, the majority (up to 95%) of IPP and DMAPP is derived via the MEP pathway (Wang et al., 2001). Starting from these precursors, geranyl diphosphate (GPP) is formed, which, through a series of enzyme-catalyzed reactions and intermediate transformations, gives rise to loganic acid, the direct precursor to Sweroside. The stepwise elucidation of this pathway provides critical direction for future exploration into the biosynthesis of Sweroside (Figure 1).

FIGURE 1

In addition to this, the accumulation of secondary metabolites in plants often demonstrates notable organ and tissue specificity. For instance, in the aerial reproductive structures of Gentiana pneumonanthe, Sweroside constitutes the predominant metabolite (Popovic et al., 2019). Similarly, in Swertia mussotii, the distribution of secoiridoid glycosides varies distinctly across different tissues. Interestingly, studies have revealed an apparent disconnect between the expression patterns of key biosynthetic genes and the spatial variability in metabolite distribution, suggesting the involvement of highly complex regulatory systems (Liu et al., 2017). Factors such as metabolic enzyme activity, substrate availability, and the cellular microenvironment likely contribute to these nuanced distribution patterns, thereby presenting niche for future investigations into underlying regulatory mechanisms. Additionally, recent studies indicate that WRKY transcription factors may play a pivotal role in the biosynthesis of secoiridoids, exhibiting close associations with the expression of GmWRKY genes. For example, treatment with methyl jasmonate (MeJA) led to increased expression of GmWRKY genes and enzymes implicated in Sweroside biosynthesis. However, paradoxically, this did not significantly enhance Sweroside content (Yin et al., 2024), suggesting the existence of unidentified regulatory mechanisms. Potential factors may include enzyme activity modulation, metabolic network crosstalk, or sophisticated regulation of signaling pathways.

Although the biosynthetic pathways and regulatory mechanisms underlying Sweroside remain incompletely mapped, existing studies have laid a solid groundwork for unraveling its molecular basis and metabolic architecture. These advances not only provide a scientific foundation for optimizing industrial extraction and production processes of Sweroside but also serve as a springboard for exploring the biosynthesis and metabolic engineering of other secoiridoid metabolites.

4 Pharmacological activities of sweroside: mechanisms and pathway insights

4.1 Anti-inflammatory potential of sweroside: unraveling its molecular targets

Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) is a pivotal transcription factor that orchestrates the expression of pro-inflammatory cytokines, such as IL-6 and TNF-α, and plays a central role in the inflammatory response (Wang B. et al., 2024). Numerous studies have demonstrated that Sweroside exerts potent anti-inflammatory effects by significantly reducing the release of pro-inflammatory cytokines, including IL-6 and IL-8, through the inhibition of NF-κB activity. This mechanism positions Sweroside as a promising therapeutic agent for various inflammatory diseases (Jiang et al., 2014). For instance, in the context of cardiovascular diseases, Sweroside effectively suppresses inflammation in cardiomyocytes by modulating the CaMKIIδ/NF-κB/NLRP3 signaling pathway. Specifically, Sweroside directly binds to CaMKIIδ, mitigating ROS-mediated inflammatory signaling induced by Angiotensin II (Ang II). This action inhibits the activation of the NF-κB/NLRP3 inflammasome, significantly alleviating heart failure caused by cardiac overload (Wang D. et al., 2024). Similarly, Sweroside reduces inflammation-induced damage during myocardial ischemia-reperfusion by inhibiting NF-κB/NLRP3 activation (Li et al., 2021).

Notably, Sweroside also enhances its anti-inflammatory effects through the activation of the deacetylase SIRT1. This activation leads to reduced expression of inflammation-related enzymes, such as iNOS and COX-2, and a decrease in pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6. Concurrently, Sweroside promotes the production of the anti-inflammatory cytokine IL-10 (Wang et al., 2019). This dual action of inhibiting pro-inflammatory mediators while enhancing anti-inflammatory responses underscores its therapeutic potential in treating conditions such as osteoarthritis, heart failure, and diabetic nephropathy. In animal models, Sweroside has been shown to alleviate acute lung injury (ALI) and pulmonary edema induced by lipopolysaccharide (LPS). This effect is achieved by upregulating SIRT1 expression, reducing NF-κB p65 and IκBα activation, and downregulating TNF-α and IL-1β secretion. Importantly, inhibition of the SIRT1 pathway markedly diminishes the protective effects of Sweroside, further validating the critical role of SIRT1 activation in its anti-inflammatory mechanism (Wang et al., 2021). These findings provide a novel therapeutic strategy and molecular basis for managing inflammatory diseases, including pneumonia.

In addition to its role in cardiovascular and pulmonary conditions, Sweroside displays substantial anti-inflammatory and bone-regulating effects in osteoarthritis and rheumatoid arthritis. Studies have shown that Sweroside dose-dependently inhibits NF-κB activation in MC3T3-E1 osteoblasts by reducing IKKα and p-NF-κB protein levels while upregulating IκB expression. This regulation enhances mineralized nodule formation and increases the expression of osteoblast-related markers, such as RUNX2, COL1A1, OCN, and OPG, while simultaneously inhibiting RANKL expression. Furthermore, Sweroside mitigates LPS-induced osteoblast inflammation by reducing TNF-α, IL-1β, and IL-6 secretion and activating the PI3K/AKT/GSK-3β/β-catenin signaling pathway (Wei L., 2021). This dual action promotes osteoblast mineralization and inhibits excessive osteoclast differentiation. In rheumatoid arthritis models, Sweroside has been shown to induce apoptosis in fibroblast-like synoviocytes by suppressing Bcl-2 expression and reducing osteoclast formation (Wu et al., 2021). This evidence highlights its potential as a therapeutic agent for regulating bone metabolism and mitigating inflammation in arthritis.

Beyond the NF-κB pathway, Sweroside also exerts anti-inflammatory effects by inhibiting the mTORC1 signaling pathway. This inhibition reduces the production of nitric oxide (NO) and prostaglandin E2 (PGE2) induced by IL-1β, as well as the expression of matrix metalloproteinases (MMP-1, MMP-3, MMP-13) and ADAMTS-5 mRNA (Zhang et al., 2019). In a rat model of chronic liver injury induced by CCl4, Sweroside was administered at doses ranging from 75 to 250 mg/kg. Moreover, no toxicity was observed within the experimental dose range, and 125 mg/kg significantly alleviated hepatic inflammation and promoted liver repair. Histological analysis showed a reduction in inflammatory cell infiltration and alleviation of inflammatory damage in liver tissue. And in vitro experiments, Sweroside reduced the source of inflammatory cells by inhibiting the proliferation of HSCs, thereby alleviating the inflammatory response in liver tissue (Gong et al., 2020). Additionally, Sweroside inhibits the activity of key inflammatory enzymes, including COX-2, iNOS, and 5-lipoxygenase (5-LOX), further contributing to its anti-inflammatory effects (Ryu et al., 2010). As a natural secoiridoid metabolites, Sweroside achieves its anti-inflammatory activity through diverse pathways and targets. For example, studies have shown that Sweroside inhibits cyclooxygenase (COX-1 and COX-2) activity, offering a safer alternative to nonsteroidal anti-inflammatory drugs (NSAIDs) due to its lower toxicity. Sweroside, extracted from Pterocephalus hookeri, has demonstrated significant anti-inflammatory effects (Wang et al., 2019). These extracts regulate the expression of iNOS and COX-2, inhibit pro-inflammatory cytokines (e.g., TNF-α, IL-1β, and IL-6), and show therapeutic efficacy in rheumatoid arthritis models.

Collectively, this body of evidence positions Sweroside as a natural anti-inflammatory metabolite with extensive effects mediated through the NF-κB and related signaling pathways, as well as other molecular targets. Its ability to regulate multiple pathways highlights its therapeutic potential in treating inflammatory diseases, including liver disorders, osteoporosis, and cardiovascular conditions. These insights provide a robust molecular foundation for the development of novel anti-inflammatory drugs based on Sweroside (Figure 2).

FIGURE 2

4.2 Antioxidant properties of sweroside: bridging cell protection with therapeutic potential

Sweroside also shows remarkable antioxidant properties. Its capacity to inhibit crucial enzymes and modulate multiple biological pathways clearly demonstrates this. Studies have identified Sweroside in Schenkia spicata, where its antioxidant and enzyme-inhibitory potential has been evaluated through both in vitro experiments and computer-aided molecular docking studies. Specifically, Sweroside demonstrates notable inhibitory effects on butyrylcholinesterase (BChE), tyrosinase, α-amylase, and glucosidase. Molecular docking analyses reveal that Sweroside interacts with BChE and tyrosinase via hydrogen bonding and van der Waals forces, highlighting its potential applications in neuroprotection. Similarly, its binding to α-amylase and glucosidase elucidates the molecular mechanisms underlying its anti-diabetic enzyme activity. Chemical assays, including the CUPRAC and FRAP methods, further confirm its moderate antioxidant capacity, with Sweroside facilitating the reduction of Cu²⁺ to Cu⁺ (21.14 mg TE/g) and Fe³⁺ to Fe²⁺ (12.32 mg TE/g) (Zengin et al., 2023). Although both methods showed certain reducing abilities, they cannot fully represent their antioxidant effects in biological systems. And the molecular docking results may not completely correspond to the inhibition rates obtained from actual experiments, and further in vivo and in vitro experiments are needed to confirm this. Additionally, Sweroside has been shown to mitigate DNA damage induced by 4-nitroquinoline one-oxide (4-NQO), demonstrating significant anti-genotoxic activity (Deng et al., 2013). This protective effect is largely attributed to its antioxidant properties, offering new avenues for the prevention and treatment of genotoxicity-related diseases (Cvetkovic et al., 2020).

Excessive production of reactive oxygen species (ROS) is a key driver of oxidative stress and inflammation, and Sweroside has demonstrated potent efficacy in regulating ROS levels. Quantitative analyses of Cornus officinalis fruit extracts, which are rich in Sweroside, have revealed its ability to significantly inhibit ROS production. Furthermore, water-based extracts containing Sweroside effectively suppressed the release of tumor necrosis factor-α (TNF-α) by neutrophils, an effect attributed to the synergistic action of Sweroside and other bioactive metabolites. Sweroside is one of the bioactive components in Cornus extract, and the extract enriched in sweroside exhibits enhanced antioxidant and immunomodulatory properties (Czerwinska et al., 2021). In myocardial protection studies, Sweroside has shown strong protective effects against oxidative stress-induced damage. It significantly reduces ROS and malondialdehyde (MDA) accumulation, thereby inhibiting lipid peroxidation, while simultaneously increasing the activity of key antioxidant enzymes, such as superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px). Moreover, Sweroside induces the expression of heme oxygenase-1 (HO-1) and promotes the activation and nuclear translocation of Nrf2 by inhibiting the Keap1-Nrf2 interaction, thereby enhancing cellular antioxidant responses. This evidence underscores Sweroside’s regulatory role in the Nrf2-dependent Keap1/Nrf2 axis (Li et al., 2021), offering a novel mechanism for mitigating ischemia-reperfusion injury, improving myocardial viability, and reducing the release of injury biomarkers.

Oral administration of high concentrations of Sweroside extract has been shown to enhance the endogenous antioxidant defense system. This is evidenced by increased SOD and catalase (CAT) activity, elevated glutathione (GSH) levels, and a marked reduction in MDA (Dang et al., 2021). In an animal model of oxidative stress induced by CCl₄, Sweroside, as the primary active bioactive metabolites of Gentiana asclepiadea extract, significantly enhanced catalase and SOD activity, increased reduced glutathione levels, and decreased MDA content (Tao et al., 2019). These biochemical changes highlight Sweroside’s ability to bolster the oxidative stress defense system, providing robust evidence for its potential as a therapeutic antioxidant agent.

5 Sweroside in translational medicine and therapeutic applications

5.1 Hepatoprotective effects of sweroside: mechanistic insights and clinical implications

The liver, the largest visceral organ in the human body, performs an array of vital physiological functions. However, liver injury can initiate a cascade of health complications, some of which may become life-threatening. In recent years, mounting evidence has highlighted the therapeutic potential of Sweroside in liver protection, owing to its robust anti-inflammatory and antioxidant properties. Early studies from the 1990s revealed that the n-butanol (n-BuOH) extract of Swertia, which Sweroside included, exhibits significant hepatoprotective effects against D-galactosamine (D-GalN)/lipopolysaccharide (LPS)-induced liver injury in mice (Hase et al., 1997). Subsequent investigations expanded its application scope to conditions like non-alcoholic steatohepatitis (NASH). In a NASH mouse model induced by a methionine-choline-deficient (MCD) diet, intraperitoneal administration of Sweroside significantly suppressed the activation of the NLRP3 inflammasome in primary macrophages, leading to a reduction in IL-1β and caspase-1 production. This intervention not only attenuated serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels but also reduced immune cell infiltration, triglyceride accumulation, and fibrosis in liver tissues. Furthermore, Sweroside inhibited NLRP3 inflammasome activation by obstructing the de novo synthesis of mitochondrial DNA, intensifying its hepatoprotective effects. The study also employed the MTT assay to assess the cytotoxicity of Sweroside on cells, and it was observed that treatment with Sweroside up to 100 μM did not induce significant cytotoxicity. (Yang G. et al., 2020). Collectively, these advances underscore Sweroside’s anti-inflammatory and antioxidant efficacy in various liver injury models. But the study only observed the short-term effects of Sweroside and cannot determine the impact of long-term Sweroside treatment on the pathological process. In addition to inflammation, fat accumulation, and fibrosis, the pathological features of NASH also include insulin resistance, oxidative stress, etc. The study failed to evaluate the effect of Sweroside on these pathological features, so it is impossible to fully understand the role of Sweroside in the overall pathological process of NASH.

Non-alcoholic fatty liver disease (NAFLD), a complex metabolic liver disorder, is closely linked to heightened liver-related morbidity and mortality and is a precursor to other diseases, including type 2 diabetes (Ballestri et al., 2016) and atherosclerosis (Mikolasevic et al., 2016). The activation of peroxisome proliferator-activated receptor α (PPAR-α) emerges as a critical mechanism in mitigating NAFLD by promoting anti-inflammatory gene expression and suppressing inflammatory mediators (Bougarne et al., 2018). In a study using C57BL/6 mice (HFD) model, Sweroside treatment at doses of 120 mg/kg and 240 mg/kg significantly reduced weight gain, improved glucose tolerance and insulin sensitivity, mitigated hepatic steatosis, lowered serum lipid levels, and diminished liver inflammation. These effects were strongly associated with the activation of PPAR-α (Yang Q. L. et al., 2020). Moreover, in vitro analyses revealed that the main metabolite of Sweroside in the rats’ body, Sweroside aglycone (Sweroside-M1), could activate PPAR-α transcription, offering an additional avenue for its therapeutic effects on NAFLD. By leveraging this dual mechanism, Sweroside opens new possibilities for NAFLD treatment. The duration of the trial was 6 weeks, which may not be sufficient to investigate the long-term efficacy and potential chronic toxicity of Sweroside in NAFLD.

Bile acid regulation is pivotal within the enterohepatic system, yet excessive bile acid accumulation in the liver can directly or indirectly induce hepatocyte injury (Chatterjee et al., 2014). Recent findings have highlighted Sweroside’s protective role in cholestatic liver diseases (Malhi et al., 2010). In ANIT-induced C57BL/6J mice model, mice treated with Sweroside (120 mg/kg), the compound significantly downregulated the expression of bile acid synthesis-related genes (e.g., CYP7A1, CYP8B1, and HSD3B7) while concurrently inhibiting the expression of bile acid transporters, such as Mrp2, Ost-β, Mdr1, NTCP, Oatp1a1, and Oatp1b2 (Yang et al., 2016). This regulatory activity diminished pro-inflammatory responses and alleviated liver-specific injuries. In this experiment, Sweroside markedly reduced the expression of pro-inflammatory markers and normalized elevated serum ALT and AST levels, alleviating hepatocyte necrosis. Additionally, it reversed the increase in serum alkaline phosphatase (ALP), total bilirubin (TBIL), direct bilirubin (DBIL), and total bile acids (TBA) caused by ANIT exposure, improving liver-function indicators. Importantly, these investigations reported no observable toxicity for Sweroside in either cellular or animal models, further substantiating its safety profile as a promising therapeutic candidate. In liver protection mechanisms, cytochrome P450 (CYP450) enzyme regulation represents a pivotal area of focus (Dai et al., 2018). Specifically, CYP3A4—the most abundant CYP isoenzyme in the liver—is instrumental in bile acid metabolism and drug detoxification. Studies suggest that CYP3A4 also has therapeutic implications in mitigating aconitine-induced toxicity. HepG2 cell studies demonstrated that amarogentin exhibits strong binding affinity to CYP3A4, inducing its mRNA expression, thereby expediting aconitine metabolism and reducing its hepatotoxicity. Although Sweroside’s binding score is lower than that of Amarogentin, it is higher than that of some other compounds such as Loganic acid and Swertiamarin, indicating that it may have certain potential in regulating CYP3A4. However, the study was only conducted in HepG2 cells, with a lack of in vivo experimental data. Moreover, there are no existing studies that have deeply explored the mechanism of action of Sweroside, such as its impact on CYP3A4 protein expression and enzyme activity. And future studies need to verify the efficacy and safety of Sweroside in animal models, further investigate its mechanism of action.

In addition, Sweroside’s hepatoprotective potential is further supported by findings from studies on Gentianaceae plant extracts rich in Sweroside. Extracts from the aerial parts and roots of Gentiana asclepiadea L. (Mihailovic et al., 2013b) and Gentiana cruciata L. (Mihailović et al., 2014) increased CAT, SOD, and GSH levels in a CCl₄-induced liver injury model while significantly reducing MDA levels, thereby ameliorating oxidative-stress-induced liver damage. Similarly, in Gentianella turkestanerum, the butanol extract, with its high secoiridoid glycoside content, exhibited superior efficacy in alleviating acute liver injury compared to other extracts (Yang et al., 2017). These extracts reversed reductions in SOD, GSH, and CAT activity in a dose-dependent manner, further corroborating their hepatoprotective properties. In summary, Sweroside exhibits multifaceted therapeutic potential in liver-disease models, functioning through anti-inflammatory, antioxidant, bile acid regulatory, and mitochondrial DNA synthesis enhancement mechanisms. These findings not only underscore the value of Sweroside as a drug candidate but also present innovative strategies for the clinical management of liver diseases, paving the way for novel therapeutic interventions (Figure 3).

FIGURE 3

5.2 Sweroside in osteoporosis management: stimulating bone formation and repair

Osteoporosis, a prevalent metabolic bone disease, is characterized by an imbalance between bone formation and resorption, with osteoblast proliferation and differentiation playing a pivotal role in its treatment (Almeida et al., 2017; Christenson, 1997). Sex steroid hormones and their receptors are intimately linked to bone metabolism, and maintaining this delicate balance is essential for effective therapeutic strategies. Sweroside has demonstrated significant potential in regulating bone metabolism through multiple mechanisms. Studies have identified Sweroside as a key active metabolite in the traditional Chinese medicine Xianlinggubao Capsule (XLGB), where it activates adenylate cyclase (AC) to promote the biosynthesis of sex steroid hormones. By enhancing hormone synthesis, Sweroside contributes to the maintenance of bone health and the prevention of osteoporosis (Tang et al., 2021).

Beyond its endocrine regulatory effects, the antioxidant properties of Sweroside further bolster its anti-osteoporotic efficacy. Extracts of Gentiana macrophylla Pall., rich in Sweroside, have exhibited potent antioxidant activity in DPPH, NBT, and FRAP assays, with IC₅₀ values of 275, 262, and 180 μg/mL, respectively, in a concentration-dependent manner. These extracts also reduced serum ALP levels, decreased urinary calcium excretion, and increased serum calcium concentrations, suggesting a protective effect against osteoporosis mediated by antioxidant mechanisms. Sweroside, as a key bioactive metabolite of these extracts, likely contributes to these observed benefits, further emphasizing its multifaceted role in bone health (Gong et al., 2018). Sweroside’s ability to promote osteoblast proliferation and differentiation adds another dimension to its therapeutic potential. In studies using Sweroside extracted from Cornus officinalis fruits, the metabolite significantly enhanced the proliferation of human MG-63 cells and rat osteoblasts (P < 0.01) without exhibiting cytotoxicity at concentrations of 10^–5 and 10^–6 g/mL. Furthermore, Sweroside treatment increased ALP activity in MG-63 cells and rat osteoblasts by approximately 1.4- and 1.3-fold (P < 0.05), respectively, and significantly elevated osteocalcin secretion compared to control groups (P < 0.05). These findings indicate that Sweroside directly promotes osteoblast differentiation, suggesting that its anti-osteoporosis effects stem from its ability to enhance osteogenic function (Sun et al., 2013). In the experiment, two cell models, human MG-63 cells and rat osteoblasts, were used to comprehensively evaluate the osteogenic effect of Sweroside by MTT assay, ALP activity assay, osteocalcin secretion assay and flow cytometry. However, there is a lack of in vivo experiments, making it difficult to evaluate the long-term effects of drugs.

Mechanistic studies have further elucidated Sweroside’s osteogenic efficacy. By activating the p38 signaling pathway through interactions with membrane estrogen receptor-α and GPR30, Sweroside enhances the differentiation and mineralization efficiency of MC3T3-E1 pre-osteoblasts (Wu et al., 2020). The limitations of this study include the absence of in vivo experiments and a lack of long-term efficacy assessment like the experiments conducted by Sun et al. (2013) Nevertheless, both experiments provide robust evidence supporting the potential therapeutic application of Sweroside in osteoporosis treatment. The findings from the first experiment offer a more comprehensive evaluation across multiple parameters, whereas the current study delves deeper into elucidating the underlying molecular mechanisms of action. Additionally, Sweroside regulates the expression of key proteins and transcription factors involved in osteogenesis. In an ovariectomized (OVX) mouse model, Sweroside significantly upregulated the expression of osteogenesis-related genes, including RUNX2, OSX, OCN, Collagen I, BMP2, and OPN, by activating the mTORC1/PS6 signaling pathway. The most pronounced effects were observed at a concentration of 1 μg/mL. This mechanism facilitates the differentiation of bone marrow mesenchymal stem cells (BMSCs) into osteoblasts, effectively mitigating menopause-related osteoporosis (Ding et al., 2019). Furthermore, Sweroside promotes the formation of mineralized bone matrix by regulating the BMP2/CBFA1 signaling pathway, providing critical support for bone repair and the generation of new bone tissue (Choi et al., 2021).

Studies have indicated that Sweroside may exert anti-osteoporotic effects through multiple mechanisms, such as regulating endocrine function, enhancing antioxidant activity, promoting the proliferation and differentiation of osteoblasts, and inhibiting their apoptosis, which are mediated by the activation of key signaling pathways. Most existing studies are limited to in vitro cell experiments, lacking in-depth investigations into its long-term efficacy and mechanism of action in vivo. Future research should include more in vivo experiments, clarify its targets and signal transduction mechanisms, so as to facilitate the application of Sweroside in the treatment of osteoporosis. In brief, Sweroside exerts its anti-osteoporotic effects through a multi-targeted approach, including antioxidant mechanisms, direct promotion of osteoblast proliferation and differentiation, and regulation of key signaling pathways such as mTORC1 and BMP2/CBFA1. These works establish Sweroside as a promising natural metabolite with significant potential for the prevention and treatment of osteoporosis, offering a comprehensive strategy to address the multifactorial nature of this disease (Figure 4).

FIGURE 4

5.3 Sweroside as an anti-cancer agent: targeting tumor growth and pathway regulation

Sweroside has garnered considerable attention for its multi-target anti-cancer properties. Inhibiting tumor cell proliferation, inducing cell cycle arrest and apoptosis, and suppressing tumor growth in vivo are all manifestations of anti-cancer activity (Chen et al., 2024). This section explores the mechanisms by which Sweroside regulates cell proliferation, apoptosis, and signaling pathways, while highlighting its potential application in cancer therapy. Sweroside exerts its anti-cancer effects by modulating key signaling pathways involved in tumor metabolism and growth. In a liver cancer model, Sweroside and gentiopicroside exhibited synergistic anti-cancer effects by jointly activating the Akt and Erk1/2 signaling pathways (Huang et al., 2016). This activation resulted in the suppression of phosphoenolpyruvate carboxykinase 1 (Pck1), a metabolism-related enzyme that is frequently overexpressed in various cancers. The combination of these compounds significantly enhanced the activity of Akt and Erk1/2 signaling, amplifying the inhibitory effects on tumor cells. By reducing Pck1 levels, Sweroside disrupts tumor metabolism, a mechanism of considerable importance for therapeutic strategies targeting metabolic disorders in cancer.

Beyond its metabolic regulation, Sweroside’s ability to modulate the cell cycle and induce apoptosis forms the core of its anti-cancer mechanisms. Studies on acute myeloid leukemia (AML) revealed that Sweroside significantly inhibited the proliferation of human leukemia cell lines in vitro, with half-maximal inhibitory concentration (IC₅₀) values ranging from 62.58 to 318.60 µM. Sweroside exhibits significant anti-leukemia activity in the range of 40–80 µM (in vitro) and 50–100 mg/kg (in vivo), with its mechanism of action achieved through dual pathways of cell cycle arrest and apoptosis. Importantly, Sweroside exhibited lower toxicity toward normal cell lines, establishing a favorable safety profile for its clinical application. Mechanistic investigations showed that Sweroside induced S and G2/M phase cell cycle arrest in HL-60 leukemia cells by downregulating cell cycle regulatory proteins Cyclin D1, CDK4, and CDC2, while upregulating cell cycle inhibitors p53 and p21. This dual effect effectively halts leukemia cell proliferation. Concurrently, Sweroside activated multiple apoptosis-related pathways, increasing the expression of Cleaved Caspase-9, Caspase-3, and PARP, while reducing the anti-apoptotic protein Bcl-2 and upregulating the pro-apoptotic protein Bax (Han et al., 2017). This cascade of molecular events triggers programmed cell death, thereby blocking further tumor progression.

Similar mechanisms have been observed in solid tumor studies. For instance, the methanol extract of Gentiana kurroo roots, which is rich in Sweroside, exhibited potent anti-cancer effects against pancreatic cancer cells (Miapaca-2). This extract induced G0/G1 phase cell cycle arrest and triggered programmed cell death, demonstrating Sweroside’s comprehensive regulation of the cell cycle and apoptosis (Wani et al., 2013). In glioblastoma (U251 cell) models, Sweroside showed high anti-proliferative activity, mediated by its inhibition of the JNK/p38 MAPK signaling pathway. This pathway is critical for cancer cell proliferation and survival. Sweroside also enhanced the expression of pro-apoptotic proteins Caspase-3, Caspase-9, and Bax, while suppressing the anti-apoptotic protein Bcl-2, thereby promoting apoptosis in glioblastoma cells (Ouyang and Xu, 2019). The 5–20 µM range shows significant anti-tumor activity against U251 glioblastoma cells. The IC50 of Sweroside for U251 cells (10 µM) is much lower than that for normal astrocytes (100 µM), supporting its targeting. Since this study is only in vitro data, additional animal model validation is needed to confirm in vivo efficacy. In addition to inhibiting cancer cell proliferation, Sweroside also effectively suppresses cancer cell metastasis. It achieves this by modulating the Wnt/β-catenin signaling pathway, thereby inhibiting the transcriptional activity of β-catenin and downregulating the expression of downstream target genes, including c-myc, Cyclin D1, Survivin, and MMP-7. Furthermore, Sweroside reduces the ability of cancer cells to form spheroids and colonies while decreasing the expression of stem cell markers CD133 and CD44. These actions collectively inhibit cancer cell proliferation, invasion, and migration, and block the acquisition of stem cell-like properties (Huang et al., 2021). As a result, Sweroside holds significant potential as a therapeutic agent for prostate cancer (PCa) bone metastasis. These findings underscore Sweroside’s potential as a therapeutic agent for highly invasive tumors.

Collectively, these studies highlight the multidimensional anti-cancer activity of Sweroside, which encompasses direct regulation of the cell cycle, promotion of apoptosis, and fine-tuning of multiple signaling pathways (Figure 5). Moreover, the combination of Sweroside with other metabolites, such as gentiopicroside, has been shown to amplify its anti-cancer effects through synergistic interactions. This suggests that Sweroside’s therapeutic potential extends beyond its use as a standalone agent, offering valuable insights into combination therapies and targeted interventions. Sweroside has demonstrated significant anti-tumor potential in various cancer models, exerting its effects by inhibiting cell proliferation, inducing apoptosis, arresting the cell cycle, and regulating signaling pathways. Existing studies lack long-term in vivo experimental data, the mechanism of action remains incompletely clarified, and drug resistance has not been evaluated. Future research should conduct long-term in vivo experiments to assess its long-term efficacy and toxicity, and explore its mechanism of action in depth. Additionally, attempts can be made to conduct combined studies with other multi-target drugs to evaluate whether it can overcome drug resistance or enhance therapeutic effects.

FIGURE 5

5.4 Sweroside in diabetic nephropathy: improving podocyte function and glucose metabolism

Diabetic nephropathy (DN), a leading chronic complication of diabetes, arises from a multifaceted pathogenesis involving oxidative stress, inflammation, metabolic dysregulation, and apoptosis. Recent studies have highlighted Sweroside as a promising therapeutic agent for DN, demonstrating protective effects through diverse mechanisms and offering new avenues for the treatment of diabetes and its associated complications. One of Sweroside’s key therapeutic actions is its ability to protect podocytes from high glucose (HG)-induced injury and apoptosis. In C57BL/6 mice model of DN, 120 mg/kg/day by gavage for 3 months, Sweroside significantly improved podocyte structure and function, stabilizing the glomerular filtration barrier by upregulating nephrin and podocin expression. Concurrently, it downregulated desmin and hypoxia-inducible factor-1α (HIF1α), markers associated with pathological damage, thereby mitigating DN-induced functional impairments. Moreover, Sweroside alleviated proteinuria, glomerular injury, and metabolic disturbances by activating the Akt/BAD signaling pathway. Specifically, it increased the expression of the pro-survival protein BAD and phosphorylated Akt (p-Akt), shielding podocytes from HG-induced damage and apoptotic signals (Huang et al., 2023).

In addition to its protective effects on podocytes, Sweroside exhibits potent anti-inflammatory and antioxidant properties. By modulating the SIRT1/NF-κB signaling pathway (Ma et al., 2023), Sweroside at 100 μM upregulated SIRT1 expression, facilitating the deacetylation of the p65 NF-κB subunit and thereby reducing inflammatory damage in HK-2 proximal tubular epithelial cells. This mechanism highlights Sweroside’s ability to attenuate inflammation by targeting key inflammatory signaling pathways. Oxidative stress is also one of the causes of diabetes and its complications (Darenskaya et al., 2021). Future studies should incorporate animal models to provide a more comprehensive assessment of Sweroside’s therapeutic potential for DN. Furthermore, Sweroside demonstrated robust antioxidant activity, reducing oxidative stress levels and inhibiting free radical production. These effects further alleviate oxidative stress-induced cellular damage, providing a strong theoretical basis for its role in mitigating diabetes-related complications. Beyond its renal protective properties, Sweroside also plays a critical role in regulating glucose metabolism. Gluconeogenesis, a key metabolic pathway contributing to hyperglycemia in diabetes, is driven by Pck1, an enzyme central to blood glucose regulation. Studies have shown that Sweroside, alone or in combination with gentiopicroside, significantly suppresses Pck1 expression in HL1C cells, mimicking insulin-like effects by inducing the phosphorylation of Akt and Erk1/2 signaling pathways (Huang et al., 2016). This synergistic mechanism underscores the potential of Sweroside and gentiopicroside in regulating gluconeogenesis and addressing metabolic dysregulation. Additionally, Sweroside has demonstrated broader metabolic regulatory effects. For instance, in the chloroform fraction of Anthocleista vogelii root bark, Sweroside exhibited dose-dependent inhibition of α-amylase and α-glucosidase activity, improving glucose tolerance in obese diabetic animal models and increasing serum insulin levels (Anyanwu et al., 2019).

Taken together, Sweroside may exerts protective effects in diabetic nephropathy through multiple mechanisms, including the regulation of podocyte injury, modulation of key signaling pathways, and improvement of glucose metabolism. Its ability to reduce oxidative stress and inflammatory damage further enhances its therapeutic potential as a multi-target natural metabolite. Future studies could investigate the specific molecular mechanisms underlying the therapeutic effects of Sweroside in diabetic nephropathy (DN) from aspects such as antioxidant activity, anti-inflammatory effects, and regulation of cellular signaling pathways, as well as its differential roles in various renal cell types. Additionally, research could be conducted on the efficacy of combining Sweroside with other kidney disease treatment methods to explore its potential value in comprehensive therapy.

5.5 Cardioprotective effects of sweroside: a multi-pathway approach to myocardial health

Sweroside, a naturally derived metabolite with a unique cyclopentane core, possesses marked biological activity and holds significant promise in alleviating a spectrum of pathological myocardial injuries (Zhang et al., 2020). Its robust antioxidant and anti-inflammatory properties, particularly within the cardiovascular system, have garnered increasing attention. Recent investigations have uncovered the vital role of Sweroside in myocardial protection, achieved through multifaceted regulatory mechanisms targeting inflammation, oxidative stress, apoptosis, and metabolic dysregulation.

In the context of myocardial ischemia/reperfusion (MI/R) injury, the NLRP3 inflammasome plays a pivotal role in driving myocardial damage through pyroptosis, an inflammatory form of programmed cell death (Mezzaroma et al., 2021). Studies have demonstrated that Sweroside effectively inhibits the expression of NLRP3, ASC, IL-1β, and Caspase-1, thus suppressing the activation of the inflammasome and mitigating pyroptosis. This mechanism significantly reduces cardiomyocyte injury in MI/R models (Li et al., 2021). Furthermore, in a chronic heart failure mouse model induced by isoproterenol (ISO), Sweroside alleviated myocardial energy metabolism disturbances by upregulating Na⁺/K⁺-ATPase (ATP1A1) expression, indicating its potential to improve cardiomyocyte function by modulating metabolic processes (Qing et al., 2019). These researches suggest that Sweroside exerts protective effects in myocardial injury by synergizing anti-inflammatory and metabolic regulatory mechanisms. Innovatively, combining Sweroside with exosomes derived from mesenchymal stem cells (MSCs) has been shown to amplify its cardioprotective effects. This combined therapy, particularly in sepsis-induced myocardial damage, demonstrated superior efficacy in reducing oxidative stress, apoptosis, and inflammatory responses, underscoring the therapeutic advantage of such integrative approaches (Wang et al., 2023). Additionally, in experimental models of pressure overload (TAC/Ang II-induced myocardium damage), Sweroside effectively inhibited the CaMKIIδ/NF-κB/NLRP3 signaling axis, further illustrating its capacity to target upstream regulators of inflammation and apoptosis in myocardial injury (Wang D. et al., 2024). This study used in vitro cell models and in vivo mouse models, and used a variety of experimental methods to rigorously reveal the mechanism of Sweroside’s improvement of heart failure. Compared to other cardioprotective effects experiments, this experiment has positive controls. Sweroside demonstrates comparable efficacy to the positive control drug Captopril in improving cardiac function and alleviating myocardial fibrosis. However, it exhibits potential advantages in anti-inflammatory effects, direct targeting of CaMKIIδ, multi-target mechanisms, and its origin as a natural product.

The cardioprotective properties of Sweroside extend to mitigating aconitine-induced myocardial toxicity. Aconitine exposure in H9c2 cardiomyocytes elicits pathological hallmarks such as oxidative stress, calcium overload, mitochondrial dysfunction, autophagy dysregulation, and apoptosis. Sweroside’s treatment effectively inhibited the production of intracellular ROS induced by Aconitine and significantly downregulated the mRNA levels of LC3-II, Beclin-1, and Caspase-3 induced by Aconitine. Experimental evidence indicates that Sweroside restores calcium homeostasis by modulating the expression of Ca²⁺-handling proteins, including NaV1.5, RyR2, DHPR, and SERCA, thereby preventing calcium overload and its downstream pathological consequences. Moreover, Sweroside safeguards mitochondrial membrane potential (ΔΨ), stabilizing intracellular calcium dynamics and mitigating aconitine-induced cell injury (Ma et al., 2018). Sweroside’s ability to suppress autophagy and apoptosis induced by Aconitine further highlights its significance as a potential therapeutic agent for myocardial injuries arising from exogenous toxins. This study provides valuable insights into the mechanisms underlying the cardioprotective effects of Sweroside. Sweroside also demonstrates efficacy in counteracting pathological myocardial hypertrophy, a key contributor to the progression of numerous cardiovascular diseases. This pathological condition is tightly linked to the activation of the Akt/mTOR/HIF-1α signaling axis. By inhibiting this pathway, Sweroside attenuates the hypertrophic response, marked by reductions in H9c2 cardiomyocyte surface area and suppression of hypertrophy-associated markers such as ANP and β-MHC. Additionally, it decreases the expression of phosphorylated Akt, mTOR, and HIF-1α, thereby preventing pathological myocardial remodeling through metabolic reprogramming and pathway regulation (Chen et al., 2021).

To sum up, Sweroside exhibits potent cardioprotective effects through a variety of biological mechanisms, including modulation of inflammatory and pyroptosis signaling pathways, improvement of energy metabolism, restoration of calcium homeostasis, and reversal of pathological myocardial remodeling. These findings highlight the ability of Sweroside to alleviate myocardial hypertrophy and heart failure, as well as its potential for preventing and treating MIRI and DICT. The accumulated evidence provides a robust theoretical foundation for exploring the clinical applications of Sweroside in cardiovascular medicine. However, future research should integrate detailed mechanistic studies with clinical trials to fully elucidate the therapeutic potential of this multifaceted compound (Figure 6).

FIGURE 6

5.6 Neuroprotection and dermatological applications of sweroside: from brain health to skin disorders

Sweroside shows notable therapeutic potential across diverse disease domains, including metabolic, cardiovascular, neurodegenerative, and dermatological conditions. Its multidimensional biological activities, especially in neuroprotection and skin pathology regulation, highlight its promise as a candidate for novel therapeutic applications.

Sweroside has demonstrated notable neuroprotective effects by modulating various pathological mechanisms underlying neurodegenerative diseases. In vitro studies using PC12h cells revealed that Sweroside significantly promotes neurite outgrowth, a crucial marker of nerve regeneration. Its effects are concentration-dependent, with neurite outgrowth at 100 µM comparable to that induced by nerve growth factor (NGF) (Chiba et al., 2011). These findings suggest that Sweroside holds promise as a therapeutic candidate for the prevention and treatment of neurodegenerative disorders. Behavioral studies further corroborate its neuroprotective potential. In scopolamine-induced Danio rerio models of cognitive impairment, Sweroside significantly improved anxiety and memory deficits, the Sweroside-treated group increased risk-taking behavior, enhanced novelty preference, and altered locomotor activity, as demonstrated through the novel water maze test (NTT), Y-maze test, and novel object recognition test (NOR). Mechanistically, Sweroside inhibited acetylcholinesterase (AChE) activity, thereby enhancing cholinergic neurotransmission. Concurrently, it boosted the activity of antioxidant enzymes, including SOD, catalase (CAT), and glutathione peroxidase (GPX), while increasing reduced GSH levels and reducing protein carbonylation (Brinza et al., 2022). Whether Sweroside has clinical relevance requires further validation in mouse models, and this study offers a hypothetical basis for future animal experiments. The neuroprotective effects of Sweroside require further evaluation in mouse models, and this study provides a hypothetical basis for future animal experiments. Another hallmark of AD pathology is the abnormal aggregation of Tau protein, which is closely linked to neuronal loss and cognitive decline. Studies have shown that Sweroside, as the primary secoiridoid glycoside in Cornus officinalis, significantly reduces the accumulation of Tau oligomers (Xu et al., 2020). This effect underscores its potential to slow disease progression and supports its candidacy as a therapeutic agent for AD. Sweroside also exhibits favorable safety profiles in central nervous system applications. In studies involving methanol extracts from Gentiana roots, Sweroside, along with other active metabolites such as gentiopicroside and swertiamarin, synergistically enhanced swimming endurance in mice. At doses of 250 and 500 mg/kg, the average swimming times increased from 10.5 min in the control group to 15.8 and 16.2 min, respectively. Additionally, Sweroside demonstrated mild analgesic activity in the tail-clip test and exhibited no significant toxicity at high doses. This evidence highlights its safety and efficacy, further evaluating its potential as a therapeutic metabolite for nervous system disorders (Özturk et al., 2002).

In addition to its neuroprotective properties, Sweroside has shown considerable promise in regulating skin health, particularly through its effects on pigment metabolism. Melanin, a pigment synthesized from tyrosine metabolism, plays a protective role against ultraviolet radiation. However, excessive melanin accumulation can lead to pigmentation disorders. Studies have demonstrated that Sweroside, at a concentration of 300 μM, significantly inhibits melanin production in melan-a cells without inducing cytotoxic effects (Saito et al., 2024). This inhibition is achieved by downregulating tyrosinase, a key enzyme in melanin biosynthesis, along with its associated proteins TRP-1 and TRP-2. Further, studies using zebrafish models revealed that Sweroside activates Akt and ERK in a dose-dependent manner, leading to reduced pigmentation and tyrosinase activity. These findings suggest that Sweroside has the potential to be developed as a skin-whitening agent and a therapeutic candidate for treating pigment-related skin disorders (Jeong et al., 2015).

Overall, the diverse biological activities of Sweroside, including its antioxidant, anti-inflammatory, and Tau protein aggregation-reducing effects in neurodegenerative diseases, as well as its enzyme-regulatory activity and safety in skin pigment metabolism, provide a strong theoretical foundation for its application across multiple disease domains (Table 2). Future research should focus on elucidating its mechanisms of action in complex pathological environments, optimizing its dosage forms and delivery strategies, and advancing its development as a multi-target therapeutic agent. These efforts could pave the way for novel treatments addressing neurodegenerative disorders, skin pigmentation abnormalities, and beyond.

6 Pharmacokinetics and advanced delivery strategies for sweroside

Sweroside, recognized for its potent anti-inflammatory and antioxidant properties, has garnered significant research attention. However, pharmacokinetic studies reveal critical limitations, including low oral bioavailability and a short systemic residence time, primarily influenced by its absorption, distribution, metabolism, and excretion characteristics. Current findings elucidate these challenges while offering potential strategies for optimization. The oral bioavailability of Sweroside is notably low, reported at merely 0.31% (Luo et al., 2009). In rat studies, following oral administration of 500 mg/kg, the majority of the metabolite was excreted unabsorbed via feces, accounting for 43.38% ± 3.2% of the dose. This poor absorption is attributed to its high hydrophilicity, which impairs its ability to traverse the intestinal epithelium and enter systemic circulation. The intestinal absorption of Sweroside primarily occurs through passive diffusion and active diffusion. Efflux transporters such as P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP), and breast cancer resistance protein (BCRP) typically restrict the absorption of drugs (Xu et al., 2020). Additionally, the presence of abundant β-glucosidase in human feces accelerates its degradation, further reducing absorption efficiency (Chang et al., 2022). The first-pass metabolism effect compounds this issue, as partial deactivation occurs in the liver during gastrointestinal absorption.

Beyond absorption, the distribution profile of Sweroside is characterized by rapid plasma clearance and limited systemic retention. Intravenous administration of 1 mg/kg in rats revealed a rapid decline in plasma concentrations, equilibrating within 120 min, with a half-life of 33.9 ± 5.2 min and an absolute bioavailability of 11.90% ± 1.33%. Organ distribution studies indicate that Sweroside predominantly accumulates in the kidneys, liver, spleen, and lungs, with minimal penetration across the blood-brain barrier (BBB). This restricted BBB permeability suggests limited potential for central nervous system (CNS) applications. Comparatively, oral administration (5, 10, 15 mg/kg) resulted in delayed plasma concentration peaks (within 60 min) and a slightly extended half-life of 74.5 ± 12.3 min. However, the combined effects of delayed absorption and rapid degradation further constrained its systemic exposure (Bozunovic et al., 2018). Metabolic studies provide additional insights into Sweroside’s pharmacokinetics, highlighting its susceptibility to rapid biotransformation. Using UHPLC/Q-TOF-MS, researchers identified key metabolic pathways, including reduction, N-heterocyclization, N-acetylation, deglycosylation, and glucuronidation (Han et al., 2014). In a gastrointestinal perfusion rat model, Sweroside was rapidly converted into metabolites naucledal and epinaucledal, with naucledal exhibiting significantly higher plasma exposure (threefold greater AUC). This suggests that naucledal may represent the primary active metabolite (Li et al., 2024). Furthermore, in vitro studies demonstrate Sweroside’s high sensitivity to β-glucosidase, as enzymatic treatment with almond β-glucosidase nearly eliminated its concentration. These findings underscore the role of external factors, such as enzymatic degradation, in limiting its bioavailability. Excretion studies further emphasize Sweroside’s rapid clearance. Following intravenous administration, plasma concentrations peaked at 6.3 ± 0.4 μM within 30 min, with an elimination half-life (t1/2) of 0.4 ± 0.1 h and a mean residence time of 0.7 ± 0.1 h. The plasma clearance rate was notably high at 0.6 ± 0.1 L/h/kg, with the majority of the compound excreted via urine (fe-U: 80.3% ± 24.6%). A high plasma unbound fraction (fu: 95.7%) further supports the rapid renal excretion of Sweroside, complicating efforts to maintain therapeutic plasma concentrations (Cheng et al., 2016).

Collectively, Sweroside’s pharmacokinetic limitations—low absorption efficiency, rapid distribution, early metabolism, and efficient excretion—result in suboptimal bioavailability and short systemic residence time (Table 3). Despite these challenges, potential solutions are emerging. Prodrug strategies and advanced delivery systems, such as nanotechnology, could enhance intestinal absorption and improve systemic exposure. Additionally, the pharmacological properties of metabolites, particularly naucledal and epinaucledal, warrant further investigation. Future research should focus on isolating and evaluating these metabolites, elucidating their therapeutic potential, and exploring the influence of the intestinal microenvironment on Sweroside metabolism. By addressing these pharmacokinetic barriers, Sweroside could overcome its current limitations and expand its therapeutic applications while retaining its natural pharmacological properties.

7 Conclusion and future perspectives

7.1 Mechanisms of sweroside and its limitations in studies

This review systematically examines the presence of Sweroside in medicinal plants, its biosynthetic pathways, and its physicochemical properties, while providing a comprehensive summary of its pharmacological profile and therapeutic potential. Preclinical studies have demonstrated that Sweroside exerts a broad range of effects, including anti-inflammatory, antioxidant, analgesic, hepatoprotective, anti-diabetic, antibacterial, and anticancer activities. These effects are largely mediated through intricate interactions with key signaling pathways, such as NF-κB, NLRP3, MAPK, PI3K/Akt, Akt/BAD, mTOR, and PPAR-α, as well as regulation of pivotal molecular targets and gene expressions.

In the area of hepatoprotection, Sweroside has shown significant promise. By modulating AMPK and mTOR signaling pathways, it activates autophagy, thereby mitigating hepatic damage. It also reduces liver fibrosis through FXR regulation and attenuates lipid metabolism disturbances and inflammatory responses via PPAR-α activation. Moreover, by suppressing the NLRP3 inflammasome, Sweroside reduces the production of inflammatory cytokines, further reinforcing its hepatoprotective effects. These findings position Sweroside as a potent candidate for combating liver-pathologies. Sweroside also demonstrates compelling effects in the management of osteoporosis, where it promotes osteogenesis and enhances bone health. It facilitates the differentiation of bone marrow mesenchymal stem cells into osteoblasts through activation of the mTORC1/PS6 signaling pathway. Additionally, Sweroside contributes to the formation of a mineralized bone matrix by modulating the BMP2/CBFA1 pathway and exerts anti-inflammatory effects through the SIRT1/NF-κB and SIRT1/FOXO1 signaling pathways. By elevating alkaline phosphatase (ALP) activity and osteocalcin secretion, it significantly enhances bone mineralization and repair processes. However, studies on the effect of Sweroside on osteoblast proliferation and differentiation have mainly focused on cell experiments. In vivo models are better able to reflect the mechanism of action of drugs in the whole organism. More in vivo studies are needed in the future to further confirm its potential in the treatment of osteoporosis.

In cancer therapeutics, Sweroside has been shown to induce apoptosis in cancer cells by blocking the cell cycle, upregulating pro-apoptotic Bax expression, and downregulating anti-apoptotic Bcl-2 expression. Its ability to target these molecular pathways underscores its potential for integration into anticancer strategies. Furthermore, Sweroside exhibits remarkable efficacy in addressing diabetic nephropathy. By suppressing Pck1 expression, promoting Akt and Erk1/2 phosphorylation, and activating SIRT1-mediated p65 NF-κB deacetylation, it effectively mitigates the progression of this complex disease. This regulatory activity extends to the Akt/BAD signaling pathway, which further contributes to its protective effects on renal function. Importantly, Sweroside has shown significant therapeutic potential in alleviating myocardial injury. And it attenuates inflammatory responses, improves cardiac function, and reduces oxidative stress by targeting the NF-κB/NLRP3 pathway and modulating the Keap-1/Nrf2/ROS axis. Additionally, Sweroside decreases the release of key biomarkers such as creatine kinase-MB (CK-MB) and lactate dehydrogenase (LDH), while suppressing the production of pro-inflammatory cytokines. These effects collectively underscore its capacity to address cardiac damage and enhance recovery following myocardial injury.

In summary, Sweroside’s ability to simultaneously act on multiple targets and pathways highlights its potential as a versatile agent for the treatment of complex diseases. Its broad mechanism of action offers a solid foundation for drug development, paving the way for innovative treatments in areas such as liver disease, osteoporosis, cancer, diabetic nephropathy, and myocardial injury. However, before it is truly applied in clinical practice, the research on Swevoside still needs to be expanded and deepened. Sweroside’s specific mechanisms of action remain incompletely elucidated, the underlying mechanisms governing lipid metabolism regulation, inflammatory response modulation, and antioxidant capacity require further investigation. Current research primarily relies on animal models and in vitro experiments. While short-term treatment has shown promising outcomes, the long-term efficacy and potential side effects of Sweroside remain unclear. Future studies are warranted to further explore its mechanisms of action, optimize the drug delivery system, and evaluate its long-term efficacy and safety.

7.2 Overcoming pharmacokinetic challenges: bioavailability and toxicity assessment of sweroside

Sweroside has garnered significant attention for its therapeutic potential, yet its bioavailability and toxicity remain critical areas of investigation. In vivo studies using animal models have provided valuable insights into its pharmacokinetics, although challenges such as low oral bioavailability persist. Current data indicate that Sweroside’s poor oral bioavailability necessitates the exploration of innovative drug delivery strategies to enhance its therapeutic efficacy. Key approaches include the application of nanotechnology (Huang et al., 2021), structural modification, absorption promoters, and enzyme inhibitors.

For instance, the oil-in-water emulsion method has been employed to DFNPs loaded with secoiridoid glycosides, utilizing PLGA as a controlled-release polymer and pH-responsive polymers such as ES100 and EL30D-55 (Gao et al., 2021). This nanotechnology significantly reduces premature drug release in the stomach and small intestine, achieving controlled release in the colon and prolonging drug residence time. By optimizing polymer ratios, this method not only addresses the limitations of traditional oral formulations but also minimizes systemic absorption and associated side effects, thereby enhancing bioavailability. Such advancements hold particular promise for treating diseases like ulcerative colitis. Structural modifications further augment Sweroside’s pharmacokinetic profile. Esterification, such as the introduction of acetate groups, enhances water solubility and stability, while etherification, including benzyl ether or triphenylmethyl ether modifications, protects hydroxyl groups, improving both stability and lipophilicity (Kong et al., 2022). Cyclodextrin inclusion complexes also enhance water solubility and stability, with β-cyclodextrin increasing compound stability by approximately twofold.

Alternative drug delivery routes, such as intravenous injection or transdermal systems, offer additional solutions to bypass the first-pass effect and improve bioavailability. Transdermal systems, including liposome- or nanocarrier-enhanced plasters, increase skin permeability and enable localized drug delivery. Studies have also explored lipid nanoparticles and hydrogel formulations to improve the penetration of secoiridoid glycosides in the skin, offering potential applications in both medicine and cosmetics (Dąbrowska and Nowak, 2021). Given Sweroside’s anti-inflammatory and anti-melanin properties, its potential in developing multifunctional cosmetics for skin repair, whitening, and inflammation reduction warrants further exploration. Additional strategies, such as the use of surfactants (e.g., Tween 80) to enhance solubility and intestinal permeability, or P-glycoprotein inhibitors (e.g., cyclosporine) to reduce intestinal and hepatic metabolism, further expand the scope for optimizing Sweroside’s bioavailability (Wang M. et al., 2024). Collectively, innovations in formulation technologies, including nanocarriers, controlled-release systems, and local delivery methods, not only address pharmacokinetic limitations but also broaden Sweroside’s applicability across therapeutic and cosmetic fields.

When evaluating the clinical potential of natural products such as Sweroside, balancing therapeutic efficacy with safety is paramount. Dose-dependent toxicity remains a critical consideration in drug development, as even naturally derived metabolites can exhibit adverse effects at high doses (Li et al., 2021). Existing studies suggest that Sweroside exhibits low toxicity under most experimental conditions. For example, in studies on Gentiana asclepiadea extracts rich in Sweroside, no mortality or toxicity-related symptoms were observed at doses as high as 1,600 mg/kg, demonstrating excellent safety. Similarly, acute toxicity experiments with Palicourea rigida roots and leaves showed no toxic effects in mice (Alves et al., 2016). In cytotoxicity assays, Sweroside exhibited no significant toxicity at concentrations up to 160 μM, with only mild cytotoxicity observed at 320 μM, where cell viability remained at 77.0% (Wang et al., 2019). Furthermore, Sweroside isolated from Alsophila stems demonstrated no cytotoxicity at effective doses of 5 μM and 10 µM in TREx-HeLa-Vpr cell experiments (Win et al., 2019).

However, certain studies indicate potential toxicity under specific conditions. For instance, in the brine shrimp lethality bioassay, Sweroside exhibited an LD50 value of 34 µg/mL, suggesting moderate toxicity (Kumarasamy et al., 2003). Additionally, predictive modeling using the IRFMN/ISSCAN-CGX system estimated a carcinogenic risk value of 0.802, highlighting potential long-term risks (Sobot et al., 2020). These findings underscore the need for further validation and comprehensive toxicity assessments. Future research should prioritize long-term toxicity studies across diverse animal models, evaluate the impact of varying formulations and administration routes on toxicity, and investigate underlying mechanisms of toxicity. Moreover, systematic assessments of carcinogenicity and environmental toxicity are essential to ensure the metabolite’s safe application.

In short, while current evidence supports the safety of Sweroside at conventional doses, its toxicity profile and potential risks require further elucidation through rigorous research. Advances in formulation technologies and delivery systems have the potential to overcome existing pharmacokinetic barriers, unlocking new applications for Sweroside in both medicinal and non-medicinal fields. These efforts will lay a solid foundation for the clinical development of Sweroside, ensuring its safety and efficacy in addressing complex diseases and expanding its utility in innovative therapeutic and cosmetic products.

7.3 Future research directions and emerging applications of sweroside

Sweroside represents a promising metabolite for therapeutic innovation, with emerging research directions highlighting its potential applications across diverse disease domains. Advances in molecular biology and technology (Li et al., 2023) have provided critical insights into its mechanisms of action, offering new avenues for exploration. For instance, the Caspase family, pivotal mediators of programmed cell apoptosis and inflammation, has been identified as a key target for treating conditions such as neurodegenerative diseases, metabolic disorders, and cancers. Existing evidence suggests that Sweroside inhibits Caspase-1 while promoting the activities of Caspase-3 and Caspase-9, potentially contributing to its therapeutic effects. Additionally, the inhibition of Caspase-2 has been proposed as a targeted strategy to prevent or treat stress-induced fatty liver disease (Kim et al., 2018). This suggests that Sweroside’s capacity to ameliorate obesity and fatty liver may be linked to its regulation of lipid metabolism and inflammatory responses via Caspase-2 inhibition. However, whether its apoptotic effects involve Caspase-6 (Zheng et al., 2020) or other Caspase family members warrants further investigation.

The role of microglial NF-κB overactivation as a driving factor in neuroinflammation and neurodegenerative conditions such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and hypoxic-ischemic encephalopathy (HIE). Suppressing NF-κB activity has emerged as a promising therapeutic strategy to mitigate neuroinflammation and improve clinical outcomes (Anilkumar and Wright-Jin, 2024). Given Sweroside’s potent anti-inflammatory and antioxidant properties, its neuroprotective potential, particularly through modulation of the NF-κB pathway, represents an important direction for future research. This investigation could provide valuable insights into its role in alleviating neurodegenerative pathologies.

In the realm of metabolic diseases, the recent reclassification of non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD) reflects a more comprehensive understanding of its core pathological features (Rong et al., 2023). Unlike NAFLD, MAFLD emphasizes the interplay between hepatic fat deposition and systemic metabolic disorders such as type 2 diabetes, obesity, and metabolic syndrome, which exacerbate the risk of liver fibrosis and cardiovascular complications (Gofton et al., 2023). Current therapies, including GLP-1 receptor agonists and SGLT2 inhibitors, have demonstrated efficacy in managing MAFLD. Sweroside holds significant promise in addressing both NAFLD and MAFLD by enhancing insulin sensitivity, regulating lipid and glucose metabolism, and mitigating inflammation and oxidative stress. Notably, its ability to improve insulin sensitivity may complement the metabolic benefits of GLP-1 receptor agonists, while its antioxidant and anti-inflammatory effects could reduce oxidative stress and inflammation associated with these treatments. Future studies should explore the synergistic effects of combining Sweroside with GLP-1 receptor agonists or SGLT2 inhibitors, particularly in the context of weight management, metabolic regulation, and clinical applications.

Sweroside’s unique anti-inflammatory properties also position it as a candidate for addressing infectious diseases. Recent findings utilizing network pharmacology and molecular docking techniques reveal that Sweroside can bind to key molecular targets, including the main protease (5R82) and 3CL protease (6M2N) of SARS-CoV-2, as well as the androgen receptor (AR, 1T65). These interactions suggest its potential utility in the treatment of COVID-19 and other respiratory diseases (Wang W. X. et al., 2024). By leveraging its anti-inflammatory mechanisms, Sweroside may offer novel therapeutic strategies for managing respiratory infections. Further research should focus on elucidating its molecular targets and pathways to expand its application in infectious and respiratory diseases.

In conclusion, Sweroside exhibits broad therapeutic potential across metabolic, neurological, and infectious disease domains. By integrating modern molecular research with advanced drug development technologies, future studies can deepen our understanding of its mechanisms of action and synergistic effects. These efforts will be instrumental in translating Sweroside’s preclinical promise into clinical applications, paving the way for precision medicine and the development of innovative therapeutics (Figure 7).

FIGURE 7

References

• 1

  Achenbach H. Benirschke M. Torrenegra R. (1997). Alkaloids and other compounds from seeds of Tabernaemontana cymosa. Phytochemistry45, 325–335. 10.1016/s0031-9422(96)00645-0

  • CrossRef
  • Google Scholar

• 2

  Adepiti A. O. Nyamboki D. K. Kibrom G. B. Elujoba A. A. Spiteller M. Matasyoh J. C. (2024). Secondary metabolites from the stem bark of Alstonia boonei and the seeds of Picralima nitida with antibacterial activities. Nat. Prod. Res.29, 1–6. 10.1080/14786419.2024.2349254

  • CrossRef
  • Google Scholar

• 3

  Alhozaimy G. A. Al-Sheddi E. S. Ibrahim T. A. (2017). Biological activity and isolation of compounds from stem bark of Plumeria acutifolia. Pharmacogn. Mag.13 (Suppl. 3), S505–S511. 10.4103/pm.pm_22_17

  • CrossRef
  • Google Scholar

• 4

  Almeida M. Laurent M. R. Dubois V. Claessens F. O'Brien C. A. Bouillon R. et al (2017). Estrogens and androgens in skeletal physiology and pathophysiology. Physiol. Rev.97, 135–187. 10.1152/physrev.00033.2015

  • CrossRef
  • Google Scholar

• 5

  Alves V. G. da Rosa E. A. de Arruda L. L. Rocha B. A. Bersani Amado C. A. Santin S. M. et al (2016). Acute toxicity, antiedematogenic activity, and chemical constituents of Palicourea rigida Kunth. Z. Naturforsch. C. J. Biosci.71, 39–43. 10.1515/znc-2015-0036

  • CrossRef
  • Google Scholar

• 6

  Anilkumar S. Wright-Jin E. (2024). NF-κB as an inducible regulator of inflammation in the central nervous system. Cells13, 485. 10.3390/cells13060485

  • CrossRef
  • Google Scholar

• 7

  Anyanwu G. O. Iqbal J. Khan S. U. Zaib S. Rauf K. Onyeneke C. E. et al (2019). Antidiabetic activities of chloroform fraction of Anthocleista vogelii planch root bark in rats with diet- and alloxan-induced obesity-diabetes. J. Ethnopharmacol.229, 293–302. 10.1016/j.jep.2018.10.021

  • CrossRef
  • Google Scholar

• 8

  Asci Ö. Demirci T. Albayrak I. Deveci H. Baydar N. G. (2022). Optimization of inoculum density to support root growth and secondary metabolite accumulation in root cultures of endangered gentiana species: gentiana lutea and Gentiana boissieri. Vitro Cell. Dev. Biol.-Plant58, 1090–1098. 10.1007/s11627-022-10305-5

  • CrossRef
  • Google Scholar

• 9

  Baba H. Usifoh C. O. (2011). Phytochemical investigation and anti-inflammatory property of ethanol-water extract of the roots of Anthocleista djalonensis A. Chev. (Gentianiaceae). Afr. J. Biotechnol.10, 6598–6600. 10.5897/ajb09.625

  • CrossRef
  • Google Scholar

• 10

  Ballestri S. Zona S. Targher G. Romagnoli D. Baldelli E. Nascimbeni F. et al (2016). Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J. Gastroenterol. Hepatol.31, 936–944. 10.1111/jgh.13264

  • CrossRef
  • Google Scholar

• 11

  Bougarne N. Weyers B. Desmet S. J. Deckers J. Ray D. W. Staels B. et al (2018). Molecular actions of PPAR α in lipid metabolism and inflammation. Endocr. Rev.39, 760–802. 10.1210/er.2018-00064

  • CrossRef
  • Google Scholar

• 12

  Bozunovic J. Zivkovic S. Gasic U. Glamoclija J. Ciric A. Matekalo D. et al (2018). In vitro and in vivo transformations of Centaurium erythraea secoiridoid glucosides alternate their antioxidant and antimicrobial capacity. Ind. Crops Prod.111, 705–721. 10.1016/j.indcrop.2017.11.040

  • CrossRef
  • Google Scholar

• 13

  Brinza I. El Raey M. A. El-Kashak W. Eldahshan O. A. Hritcu L. (2022). Sweroside ameliorated memory deficits in scopolamine-induced zebrafish (Danio rerio) model: involvement of cholinergic system and brain oxidative stress. Molecules27, 5901. 10.3390/molecules27185901

  • CrossRef
  • Google Scholar

• 14

  Cai H. Cao G. Cai B. C. (2013). Rapid simultaneous identification and determination of the multiple compounds in crude fructus corni and its processed products by HPLC-MS/MS with multiple reaction monitoring mode. Pharm. Biol.51, 273–278. 10.3109/13880209.2012.720689

  • CrossRef
  • Google Scholar

• 15

  Chang Y. L. Li C. X. Wang R. F. Li X. Guo S. Z. Zhang W. et al (2022). The metabolic profile elucidation of Lonicera japonica flos water extract and the metabolic characteristics evaluation of bioactive compounds in human gastrointestinal tract in vitro. J. Pharm. Biomed. Anal.219, 114906. 10.1016/j.jpba.2022.114906

  • CrossRef
  • Google Scholar

• 16

  Changwichit K. Khorana N. Suwanborirux K. Waranuch N. Limpeanchob N. Wisuitiprot W. et al (2011). Bisindole alkaloids and secoiridoids from Alstonia macrophylla wall. Ex G. Don. Fitoterapia82, 798–804. 10.1016/j.fitote.2011.04.013

  • CrossRef
  • Google Scholar

• 17

  Chatterjee S. Bijsmans I. van Mil S. W. C. Augustijns P. Annaert P. (2014). Toxicity and intracellular accumulation of bile acids in sandwich-cultured rat hepatocytes: role of glycine conjugates. Toxicol. Vitro28, 218–230. 10.1016/j.tiv.2013.10.020

  • CrossRef
  • Google Scholar

• 18

  Chen C. Chen T. Liu Y. L. Zou D. L. You J. M. Li Y. L. (2015). Rapid screening, identification, separation, and purification of four bioactive compounds from Swertia mussotii franch. Sep. Sci. Technol.50, 604–610. 10.1080/01496395.2014.957316

  • CrossRef
  • Google Scholar

• 19

  Chen X.-Y. Chen X.-H. Li L. Su C.-P. Zhang Y.-L. Jiang Y.-Y. et al (2021). Deciphering the effective combinatorial components from si-miao-yong-an decoction regarding the intervention on myocardial hypertrophy. J. Ethnopharmacol.271, 113833. 10.1016/j.jep.2021.113833

  • CrossRef
  • Google Scholar

• 20

  Chen Y. Zhang K. Tan J. Fan Z. Fu Y. Li X. et al (2024). Design, synthesis, and pharmacological evaluation of novel benzothiazole derivatives targeting LCK in acute lymphoblastic leukemia. Bioorg. Chem.144, 107180. 10.1016/j.bioorg.2024.107180

  • CrossRef
  • Google Scholar

• 21

  Cheng C. Du F. F. Yu K. Xu F. Wang F. Q. Li L. et al (2016). Pharmacokinetics and disposition of circulating iridoids and organic acids in rats intravenously receiving ReDuNing injection. Drug Metab. Dispos.44, 1853–1858. 10.1124/dmd.116.071647

  • CrossRef
  • Google Scholar

• 22

  Chiba K. Yamazaki M. Kikuchi M. Kakuda R. Kikuchi M. (2011). New physiological function of secoiridoids: neuritogenic activity in PC12h cells. J. Nat. Med.65, 186–190. 10.1007/s11418-010-0449-y

  • CrossRef
  • Google Scholar

• 23

  Choi L. Y. Kim M. H. Yang W. M. (2021). Promotion of osteogenesis by sweroside via BMP2-involved signaling in postmenopausal osteoporosis. Phytother. Res.35, 7050–7063. 10.1002/ptr.7336

  • CrossRef
  • Google Scholar

• 24

  Christenson R. H. (1997). Biochemical markers of bone metabolism: an overview. Clin. Biochem.30, 573–593. 10.1016/s0009-9120(97)00113-6

  • CrossRef
  • Google Scholar

• 25

  Cvetkovic S. Todorovic S. Nastasijevic B. Mitic-Culafic D. Dukanovic S. Knezevic-Vukcevic J. et al (2020). Assessment of genoprotective effects of Gentiana lutea extracts prepared from plants grown in field and in vitro. Ind. Crops Prod.154, 112690. 10.1016/j.indcrop.2020.112690

  • CrossRef
  • Google Scholar

• 26

  Czerwinska M. E. Bobinska A. Cichocka K. Buchholz T. Wolinski K. Melzig M. F. (2021). Cornus Mas and cornus officinalis—A comparison of antioxidant and immunomodulatory activities of standardized fruit extracts in human neutrophils and Caco-2 models. Plants10, 2347. 10.3390/plants10112347

  • CrossRef
  • Google Scholar

• 27

  Dąbrowska M. Nowak I. (2021). Lipid nanoparticles loaded with selected iridoid glycosides as effective components of hydrogel formulations. Materials14, 4090. 10.3390/ma14154090

  • CrossRef
  • Google Scholar

• 28

  Dai K. Yi X.-J. Huang X.-J. Muhammad A. Li M. Li J. et al (2018). Hepatoprotective activity of iridoids, seco-iridoids and analog glycosides from gentianaceae on HepG2 cells via CYP3A4 induction and mitochondrial pathway. Food Funct.9, 2673–2683. 10.1039/c8fo00168e

  • CrossRef
  • Google Scholar

• 29

  Dai L. L. Cho S. B. Li H. F. Li-Sha A. Ji X. P. Pan S. et al (2023). Lomatogonium rotatum extract alleviates diabetes mellitus induced by a high-fat, high-sugar diet and streptozotocin in rats. World J. Diabetes14, 846–861. 10.4239/wjd.v14.i6.846

  • CrossRef
  • Google Scholar

• 30

  Damtoft S. Jensen S. R. Thorsen J. (1993). Kingisidic acid and 8-epi-kingisidic acid from Citronella gongonha. Phytochemistry32, 1071–1072. 10.1016/0031-9422(93)85259-t

  • CrossRef
  • Google Scholar

• 31

  Dang N. H. Thien L. D. Minh N. P. Dung D. T. Thao T. P. Lee J. H. et al (2021). Anti-osteoclastogenic activity of metabolites isolated from Viburnum lutescens blume. Phytochem. Lett.45, 13–18. 10.1016/j.phytol.2021.07.006

  • CrossRef
  • Google Scholar

• 32

  Dao P. T. A. Quan T. L. Mai N. T. T. (2015). Constituents of the stem of Nauclea orientalis. Nat. Prod. Commun.10, 1901–1903. 10.1177/1934578x1501001122

  • CrossRef
  • Google Scholar

• 33

  Darenskaya M. Kolesnikova L. A. Kolesnikov S. (2021). Oxidative stress: pathogenetic role in diabetes mellitus and its complications and therapeutic approaches to correction. Bull. Exp. Biol. Med.171, 179–189. 10.1007/s10517-021-05191-7

  • CrossRef
  • Google Scholar

• 34

  Deng S. West B. J. Jensen C. J. (2013). UPLC-TOF-MS characterization and identification of bioactive iridoids in cornus Mas fruit. J. Anal. Methods Chem.2013, 710972. 10.1155/2013/710972

  • CrossRef
  • Google Scholar

• 35

  de Oliveira P. R. Testa G. Medina R. P. de Oliveira C. M. Kato L. da Silva C. C. et al (2013). Cytotoxic activity of Guettarda pohliana müll. Arg. (rubiaceae). Nat. Prod. Res.27, 1677–1681. 10.1080/14786419.2012.761616

  • CrossRef
  • Google Scholar

• 36

  Ding Y. Chen Y. F. Hu K. Yang Q. S. Li Y. X. Huang M. J. (2023). Sweroside alleviates hepatic steatosis in part by activating AMPK/mTOR-mediated autophagy in mice. J. Cell. Biochem.124, 1012–1022. 10.1002/jcb.30428

  • CrossRef
  • Google Scholar

• 37

  Ding Y. Jiang H. J. Meng B. Y. Zhu B. Yu X. Xiang G. D. (2019). Sweroside-mediated mTORC1 hyperactivation in bone marrow mesenchymal stem cells promotes osteogenic differentiation. J. Cell. Biochem.120, 16025–16036. 10.1002/jcb.28882

  • CrossRef
  • Google Scholar

• 38

  Fadzil N. S. M. Sekar M. Gan S. H. Bonam S. R. Wu Y. S. Vaijanathappa J. et al (2021). Chemistry, pharmacology and therapeutic potential of Swertiamarin—A promising natural lead for new drug discovery and development. Drug Des. Dev. Ther.15, 2721–2746. 10.2147/dddt.s299753

  • CrossRef
  • Google Scholar

• 39

  Gao C. Yu S. Zhang X. Dang Y. Han D.-D. Liu X. et al (2021). Dual functional eudragit® S100/L30D-55 and PLGA colon-targeted nanoparticles of iridoid glycoside for improved treatment of induced ulcerative colitis. Int. J. Nanomed.16, 1405–1422. 10.2147/ijn.s291090

  • CrossRef
  • Google Scholar

• 40

  Gofton C. Upendran Y. Zheng M. H. George J. (2023). MAFLD: how is it different from NAFLD?Clin. Mol. Hepatol.29, S17–S31. 10.3350/cmh.2022.0367

  • CrossRef
  • Google Scholar

• 41

  Gong J. T. Yang F. Yang Q. L. Tang X. W. Shu F. F. Xu L. M. et al (2020). Sweroside ameliorated carbon tetrachloride (CCl4)-induced liver fibrosis through FXR-miR-29a signaling pathway. J. Nat. Med.74, 17–25. 10.1007/s11418-019-01334-3

  • CrossRef
  • Google Scholar

• 42

  Gong T. Su X. T. Xia Q. Wang J. G. (2018). Gentiana macrophylla pall (gentianaceae) extract exerts protective effects against osteoporosis in mice. Trop. J. Pharm. Res.17, 429–434. 10.4314/tjpr.v17i3.7

  • CrossRef
  • Google Scholar

• 43

  González-López O. Rodríguez-González A. Pinto C. G. Arbizu-Milagro J. Casquero P. A. (2024). Hot spots of bitter compounds in the roots of Gentiana lutea L. subsp. aurantiaca: wild and cultivated comparative. Agronomy14, 1068. 10.3390/agronomy14051068

  • CrossRef
  • Google Scholar

• 44

  Gousiadou C. Kokubun T. Gotfredsen C. H. Jensen S. R. (2015). Further iridoid glucosides in the genus manulea (scrophulariaceae). Phytochemistry109, 43–48. 10.1016/j.phytochem.2014.10.004

  • CrossRef
  • Google Scholar

• 45

  Guedes L. Reis P. Machuqueiro M. Ressaissi A. Pacheco R. Serralheiro M. L. (2019). Bioactivities of Centaurium erythraea (gentianaceae) decoctions: antioxidant activity, enzyme inhibition and docking studies. Molecules24, 3795. 10.3390/molecules24203795

  • CrossRef
  • Google Scholar

• 46

  Gülcemal D. Masullo M. Alankus-Caliskan O. Karayildirim T. Senol S. G. Piacente S. et al (2010). Monoterpenoid glucoindole alkaloids and iridoids from Pterocephalus pinardii. Magn. Reson. Chem.48, 239–243. 10.1002/mrc.2559

  • CrossRef
  • Google Scholar

• 47

  Han H. Zeng W. He C. Bligh S. W. Liu Q. Yang L. et al (2014). Characterization of metabolites of sweroside in rat urine using ultra-high-performance liquid chromatography combined with electrospray ionization quadrupole time-of-flight tandem mass spectrometry and NMR spectroscopy. J. Mass Spectrom.49, 1108–1116. 10.1002/jms.3429

  • CrossRef
  • Google Scholar

• 48

  Han X. L. Li J. D. Wang W. L. Yang C. Li Z. Y. (2017). Sweroside eradicated leukemia cells and attenuated pathogenic processes in mice by inducing apoptosis. Biomed. Pharmacother.95, 477–486. 10.1016/j.biopha.2017.08.007

  • CrossRef
  • Google Scholar

• 49

  Hase K. Li J. X. Basnet P. Xiong Q. B. Takamura S. Namba T. et al (1997). Hepatoprotective principles of Swertia japonica makino on D-galactosamine/lipopolysaccharide-induced liver injury in mice. Chem. Pharm. Bull.45, 1823–1827. 10.1248/cpb.45.1823

  • CrossRef
  • Google Scholar

• 50

  He Y.-M. Zhu S. Ge Y.-W. Kazuma K. Zou K. Cai S.-Q. et al (2015). The anti-inflammatory secoiridoid glycosides from gentianae scabrae radix: the root and rhizome of Gentiana scabra. J. Nat. Med.69, 303–312. 10.1007/s11418-015-0894-8

  • CrossRef
  • Google Scholar

• 51

  Horn M. M. Drewes S. E. Brown N. J. Munro O. Q. Meyer J. J. M. Mathekga A. D. M. (2001). Transformation of naturally-occurring 1,9-trans-9,5-cis sweroside to all trans sweroside during acetylation of sweroside aglycone. Phytochemistry57, 51–56. 10.1016/s0031-9422(00)00460-x

  • CrossRef
  • Google Scholar

• 52

  Huang J. Zhang Y. Dong L. Gao Q. Yin L. Quan H. et al (2018). Ethnopharmacology, phytochemistry, and pharmacology of Cornus officinalis Sieb. et Zucc. J. Ethnopharmacol.213, 280–301. 10.1016/j.jep.2017.11.010

  • CrossRef
  • Google Scholar

• 53

  Huang M. J. Yang Y. Chen Y. F. Li Y. Qin S. T. Xiao L. J. et al (2023). Sweroside attenuates podocyte injury and proteinuria in part by activating Akt/BAD signaling in mice. J. Cell. Biochem.124, 1749–1763. 10.1002/jcb.30484

  • CrossRef
  • Google Scholar

• 54

  Huang S. Zou C. Y. Xie S. Y. Wang B. LingHu X. T. Wang Y. X. et al (2021). Anticancer activity of sweroside nanoparticles in prostate cancer bone metastasis in PC-3 cells involved in Wnt/β-Catenin signaling pathway. J. Biomed. Nanotechnol.17, 1960–1971. 10.1166/jbn.2021.3172

  • CrossRef
  • Google Scholar

• 55

  Huang X. J. Li J. Mei Z. Y. Chen G. (2016). Gentiopicroside and sweroside from Veratrilla baillonii franch. Induce phosphorylation of akt and suppress Pck1 expression in hepatoma cells. Biochem. Cell Biol.94, 270–278. 10.1139/bcb-2015-0173

  • CrossRef
  • Google Scholar

• 56

  In S. J. Seo K. H. Song N. Y. Song M. C. An E. M. Baek N. I. (2014). Iridoids from the stems of Viburnum erosum. Holzforschung68, 761–767. 10.1515/hf-2013-0227

  • CrossRef
  • Google Scholar

• 57

  Jeong Y. T. Jeong S. C. Hwang J. S. Kim J. H. (2015). Modulation effects of sweroside isolated from the Lonicera japonica on melanin synthesis. Chem. Biol. Interact.238, 33–39. 10.1016/j.cbi.2015.05.022

  • CrossRef
  • Google Scholar

• 58

  Jia N. Chu W. Li Y. Ding L. Duan J. Cui J. et al (2016). Iridoid glycosides from the flowers of Gentiana macrophylla pall. Ameliorate collagen-induced arthritis in rats. J. Ethnopharmacol.189, 1–9. 10.1016/j.jep.2016.05.027

  • CrossRef
  • Google Scholar

• 59

  Jiang M. Han Y. Q. Zhou M. G. Zhao H. Z. Xiao X. Hou Y. Y. et al (2014). The screening research of anti-inflammatory bioactive markers from different flowering phases of flos Lonicerae japonicae. PLoS One9, e96214. 10.1371/journal.pone.0096214

  • CrossRef
  • Google Scholar

• 60

  Jonville M. C. Capel M. Frédérich M. Angenot L. Dive G. Faure R. et al (2008). Fagraldehyde, a secoiridoid isolated from Fagraea fragrans. J. Nat. Prod.71, 2038–2040. 10.1021/np800291d

  • CrossRef
  • Google Scholar

• 61

  Jovanovic M. Cujic-Nikolic N. Drinic Z. Jankovic T. Markovic S. Petrovic P. et al (2021). Spray drying of Gentiana asclepiadea L. root extract: successful encapsulation into powders with preserved stability of bioactive compounds. Ind. Crops Prod172, 114044. 10.1016/j.indcrop.2021.114044

  • CrossRef
  • Google Scholar

• 62

  Keawpradub N. Takayama H. Aimi N. Sakai S.-I. (1994). Indole alkaloids from Alstonia glaucescens. Phytochemistry37, 1745–1749. 10.1016/s0031-9422(00)89603-x

  • CrossRef
  • Google Scholar

• 63

  Kim J. Y. Garcia-Carbonell R. Yamachika S. Zhao P. Dhar D. Loomba R. et al (2018). ER stress drives lipogenesis and steatohepatitis via caspase-2 activation of S1P. Cell175, 133–145.e15. 10.1016/j.cell.2018.08.020

  • CrossRef
  • Google Scholar

• 64

  Kong Y. Yang B. Zhang J. Dong C. (2022). Research progress on hydroxyl protection of iridoid glycosides. Aust. J. Chem.75, 249–264. 10.1071/ch21260

  • CrossRef
  • Google Scholar

• 65

  Koo D. C. Baek S. Y. Jung S. H. Shim S. H. (2013). Aldose reductase inhibitory compounds from extracts of Dipsacus asper. Biotechnol. Bioprocess Eng.18, 926–931. 10.1007/s12257-013-0173-z

  • CrossRef
  • Google Scholar

• 66

  Krstic-Milosevic D. Banjac N. Jankovic T. Eler K. Vinterhalter B. (2020). Gentiana clusii perr.&Song.: enhanced production of secondary metabolites by in vitro propagation. Plant Physiol. biochem.154, 735–744. 10.1016/j.plaphy.2020.07.007

  • CrossRef
  • Google Scholar

• 67

  Kshirsagar P. R. Jagtap U. B. Gaikwad N. B. Bapat V. A. (2019). Ethanopharmacology, phytochemistry and pharmacology of medicinally potent genus swertia: an update. S. Afr. J. Bot.124, 444–483. 10.1016/j.sajb.2019.05.030

  • CrossRef
  • Google Scholar

• 68

  Kumar S. Sati O. P. Semwal V. D. Nautiyal M. Sati S. Takeda Y. (2000). Iridoid glycosides from Lonicera quinquelocularis. Phytochemistry53, 499–501. 10.1016/s0031-9422(99)00426-4

  • CrossRef
  • Google Scholar

• 69

  Kumar V. Van Staden J. (2016). A review of Swertia chirayita (gentianaceae) as a traditional medicinal plant. Front. Pharmacol.6, 308. 10.3389/fphar.2015.00308

  • CrossRef
  • Google Scholar

• 70

  Kumarasamy Y. Nahar L. Cox P. Jaspars M. Sarker S. (2003). Bioactivity of secoiridoid glycosides from Centaurium erythraea. Phytomedicine10, 344–347. 10.1078/094471103322004857

  • CrossRef
  • Google Scholar

• 71

  Lendl A. Werner I. Glasl S. Kletter C. Mucaji P. Presser A. et al (2005). Phenolic and terpenoid compounds from Chione venosa (Sw.) URBAN Var. venosa (bois bande). Phytochemistry66, 2381–2387. 10.1016/j.phytochem.2005.07.002

  • CrossRef
  • Google Scholar

• 72

  Li H. Tang S. H. Xu Y. Q. Sun Y. D. Li P. Y. Li X. N. et al (2024). In vivo detection of the epimer metabolites of sweroside via ultra-performance liquid chromatography time-of-flight mass spectrometry combined with DNPH derivatization. Biomed. Chromatogr.38, e5966. 10.1002/bmc.5966

  • CrossRef
  • Google Scholar

• 73

  Li J. Zhang J. Zuo Z. T. Huang H. Y. Wang Y. Z. (2018). Quantification and discrimination of in vitro regeneration Swertia nervosa at different growth periods using the UPLC/UV coupled with chemometric method. J. AOAC Int.101, 1473–1481. 10.5740/jaoacint.17-0488

  • CrossRef
  • Google Scholar

• 74

  Li S. Wan C. X. He L. L. Yan Z. G. Wang K. S. Yuan M. H. et al (2017). Rapid identification and quantitative analysis of chemical constituents of Gentiana veitchiorum by UHPLC-PDA-QTOF-MS. Rev. Bras. Farmacogn.27, 188–194. 10.1016/j.bjp.2016.10.003

  • CrossRef
  • Google Scholar

• 75

  Li X. Liu Q. Xie X. Peng C. Pang Q. Liu B. et al (2023). Application of novel degraders employing autophagy for expediting medicinal research. J. Med. Chem.66, 1700–1711. 10.1021/acs.jmedchem.2c01712

  • CrossRef
  • Google Scholar

• 76

  Li X. Zhang C.-T. Ma W. Xie X. Huang Q. (2021). Oridonin: a review of its pharmacology, pharmacokinetics and toxicity. Front. Pharmacol.12, 645824. 10.3389/fphar.2021.645824

  • CrossRef
  • Google Scholar

• 77

  Liang J. He J. Zhu S. Zhao W. Zhang Y. Ito Y. et al (2013a). Preparative isolation and purification of iridoid glycosides from fructus corni by high-speed countercurrent chromatography. J. Liq. Chromatogr. Relat. Technol.36, 983–999. 10.1080/10826076.2012.683914

  • CrossRef
  • Google Scholar

• 78

  Liang J. Ito Y. Zhang X. He J. Sun W. (2013b). Rapid preparative separation of six bioactive compounds from Gentiana crassicaulis duthie ex burk. Using microwave-assisted extraction coupled with high-speed counter-current chromatography. J. Sep. Sci.36, 3934–3940. 10.1002/jssc.201300897

  • CrossRef
  • Google Scholar

• 79

  Liu Y. Wang Y. Guo F. X. Zhan L. Mohr T. Cheng P. et al (2017). Deep sequencing and transcriptome analyses to identify genes involved in secoiridoid biosynthesis in the Tibetan medicinal plant Swertia mussotii. Sci. Rep.7, 43108. 10.1038/srep43108

  • CrossRef
  • Google Scholar

• 80

  Luo Y.-D. Chen J. Cao J. Wen X.-D. Li P. (2009). Determination of sweroside in rat plasma and bile for oral bioavailability and hepatobiliary excretion. Chem. Pharm. Bull.57, 79–83. 10.1248/cpb.57.79

  • CrossRef
  • Google Scholar

• 81

  Ma L.-Q. Yu Y. Chen H. Li M. Ihsan A. Tong H.-Y. et al (2018). Sweroside alleviated aconitine-induced cardiac toxicity in H9c2 cardiomyoblast cell line. Front. Pharmacol.9, 1138. 10.3389/fphar.2018.01138

  • CrossRef
  • Google Scholar

• 82

  Ma X. D. Guo Z. X. Zhao W. H. Chen L. (2023). Sweroside plays a role in mitigating high glucose-induced damage in human renal tubular epithelial HK-2 cells by regulating the SIRT1/NF-κB signaling pathway. Korean J. Physiol. Pharmacol.27, 533–540. 10.4196/kjpp.2023.27.6.533

  • CrossRef
  • Google Scholar

• 83

  Mahendran G. Bai V. N. (2014). Micropropagation, antioxidant properties and phytochemical assessment of Swertia corymbosa (griseb.) wight ex C. B. Clarke: a medicinal plant. Acta Physiol. Plant.36, 589–603. 10.1007/s11738-013-1435-2

  • CrossRef
  • Google Scholar

• 84

  Malhi H. Guicciardi M. E. Gores G. J. (2010). Hepatocyte death: a clear and present danger. Physiol. Rev.90, 1165–1194. 10.1152/physrev.00061.2009

  • CrossRef
  • Google Scholar

• 85

  Mandova T. Audo G. Michel S. Grougnet R. (2017). Off-line coupling of new generation centrifugal partition chromatography device with preparative high pressure liquid chromatography-mass spectrometry triggering fraction collection applied to the recovery of secoiridoid glycosides from Centaurium erythraea rafn. (gentianaceae). J. Chromatogr. A1513, 149–156. 10.1016/j.chroma.2017.07.023

  • CrossRef
  • Google Scholar

• 86

  Mezzaroma E. Abbate A. Toldo S. (2021). NLRP3 inflammasome inhibitors in cardiovascular diseases. Molecules26, 976. 10.3390/molecules26040976

  • CrossRef
  • Google Scholar

• 87

  Mihailović V. Katanić J. Mišić D. Stanković V. Mihailović M. Uskoković A. et al (2014). Hepatoprotective effects of secoiridoid-rich extracts from gentiana Cruciata L. against carbon tetrachloride induced liver damage in rats. Food Funct.5, 1795–1803. 10.1039/c4fo00088a

  • CrossRef
  • Google Scholar

• 88

  Mihailovic V. Matic S. Mišic D. Solujic S. Stanic S. Katanic J. et al (2013a). Chemical composition, antioxidant and antigenotoxic activities of different fractions of Gentiana asclepiadea L. roots extract. EXCLI J.12, 807–823.

  • Google Scholar

• 89

  Mihailovic V. Mihailovic M. Uskokovic A. Arambasic J. Misic D. Stankovic V. et al (2013b). Hepatoprotective effects of Gentiana asclepiadea L. extracts against carbon tetrachloride-induced liver injury in rats. Food Chem. Toxicol.52, 83–90. 10.1016/j.fct.2012.10.034

  • CrossRef
  • Google Scholar

• 90

  Mihailovic V. Stankovic J. S. K. Juric T. Sreckovic N. Misic D. Siler B. et al (2020). Blackstonia perfoliata (L.) huds. (gentianaceae): a promising source of useful bioactive compounds. Ind. Crops Prod.145, 111974. 10.1016/j.indcrop.2019.111974

  • CrossRef
  • Google Scholar

• 91

  Mikolasevic I. Milic S. Racki S. Zaputovic L. Stimac D. Radic M. et al (2016). Nonalcoholic fatty liver disease (NAFLD)—A new cardiovascular risk factor in peritoneal dialysis patients. Perit. Dial. Int.36, 427–432. 10.3747/pdi.2014.00223

  • CrossRef
  • Google Scholar

• 92

  Nikolic V. G. Troter D. Z. Savic I. M. Gajic I. M. S. Zvezdanovic J. B. Konstantinovic I. B. et al (2023). Design and optimization of “greener” and sustainable ultrasound-assisted extraction of valuable bioactive compounds from common centaury (Centaurium erythraea rafn) aerial parts: a comparative study using aqueous propylene glycol and ethanol. Ind. Crops Prod.192, 116070. 10.1016/j.indcrop.2022.116070

  • CrossRef
  • Google Scholar

• 93

  Olennikov D. N. Gadimli A. I. Isaev J. I. Kashchenko N. I. Prokopyev A. S. Kataeva T. N. et al (2019). Caucasian gentiana species: untargeted LC-MS metabolic profiling, antioxidant and digestive enzyme inhibiting activity of six plants. Metabolites9, 271. 10.3390/metabo9110271

  • CrossRef
  • Google Scholar

• 94

  Onocha P. A. Okorie D. A. Connolly J. D. Roycroft D. S. (1995). Monoterpene diol, iridoid glucoside and dibenzo-α-pyrone from Anthocleista djalonensis. Phytochemistry40, 1183–1189. 10.1016/0031-9422(95)00121-m

  • CrossRef
  • Google Scholar

• 95

  Oszmiański J. Wojdyło A. Juszczyk P. Nowicka P. (2020). Roots and leaf extracts of Dipsacus fullonum L. and their biological activities. Plants (Basel)9, 78. 10.3390/plants9010078

  • CrossRef
  • Google Scholar

• 96

  Ouyang Z. Xu G. Q. (2019). Antitumor effects of sweroside in human glioblastoma: its effects on mitochondrial-mediated apoptosis, activation of different caspases, G0/G1 cell cycle arrest and targeting JNK/p38 MAPK signal pathways. J. BUON24, 2141–2146.

  • Google Scholar

• 97

  Özturk N. Baser K. H. C. Aydin S. Öztürk Y. Çalis I. (2002). Effects of Gentiana lutea ssp. Symphyandra on the central nervous system in mice. Phytother. Res.16, 627–631. 10.1002/ptr.998

  • CrossRef
  • Google Scholar

• 98

  Pan T. H. (2023). Preparation of sweroside-based sesquiterpenoid indole alkaloid analogues and their antitumor and resistance-reversing activities (doctoral dissertation). Guiyang, Guizhou Province: Guizhou University.

  • Google Scholar

• 99

  Popovic Z. Krstic-Milosevic D. Stefanovic M. Matic R. Vidakovic V. Bojovic S. (2019). Chemical and morphological inter- and intrapopulation variability in natural populations of Gentiana pneumonanthe. L. Chem. Biodivers.16, e1800509. 10.1002/cbdv.201800509

  • CrossRef
  • Google Scholar

• 100

  Popovic Z. Milosevic D. K. Stefanovic M. Vidakovic V. Matic R. Jankovic J. et al (2021). Variability of six secondary metabolites in plant parts and developmental stages in natural populations of rare Gentiana pneumonanthe. Plant Biosyst.155, 816–822. 10.1080/11263504.2020.1785966

  • CrossRef
  • Google Scholar

• 101

  Popovic Z. Vidakovic V. Mijalkovic T. Krstic-Milosevic D. (2023). Population-related variability in qualitative and quantitative secondary metabolite profile of Gentianella austriaca (A. and J. kern.) holub. Plants (Basel)12, 2434. 10.3390/plants12132434

  • CrossRef
  • Google Scholar

• 102

  Qing W. Congping S. Huimin Z. Hui L. Wenchao J. Lin L. et al (2019). Protective effect of sweroside on heart failure induced by excessive isoproterenol in mice. J. Tianjin Univ. Tradit. Chin. Med.38, 468–472. 10.11656/j.issn.1673-9043.20

  • CrossRef
  • Google Scholar

• 103

  Radovic M. Siler B. Zivkovic J. N. Banjanac T. Zivkovic S. Nikolic M. et al (2013). Bioreactor cultivation of Zeltnera beyrichii (torr. and A. Gray) mans.: a novel source of biologically active compounds. Rec. Nat. Prod.7, 266–280.

  • Google Scholar

• 104

  Rodriguez V. Schripsema J. Jensen S. R. (1997). Iridoid glycosides from Eucnide bartonioides. Phytochemistry45, 1427–1429. 10.1016/s0031-9422(97)00162-3

  • CrossRef
  • Google Scholar

• 105

  Rong L. Zou J. Y. Ran W. Qi X. H. Chen Y. K. Cui H. J. et al (2023). Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front. Endocrinol.13, 1087260. 10.3389/fendo.2022.1087260

  • CrossRef
  • Google Scholar

• 106

  Ryu K. H. Rhee H. I. Kim J. H. Yoo H. Lee B. Y. Um K.-A. et al (2010). Anti-inflammatory and analgesic activities of SKLJI, a highly purified and injectable herbal extract of Lonicera japonica. Biosci. Biotechnol. Biochem.74, 2022–2028. 10.1271/bbb.100279

  • CrossRef
  • Google Scholar

• 107

  Saito R. Shinozaki Y. Tabata K. Nishinaka Y. Yokoyama K. Kon R. et al (2024). Tokishakuyakusan alleviates ultraviolet-induced skin pigmentation by decreasing the expression of melanogenesis-related enzymes. J. Ethnopharmacol.332, 118348. 10.1016/j.jep.2024.118348

  • CrossRef
  • Google Scholar

• 108

  Sanchez J. A. Moreno-Murillo B. Suarez L. E. C. (2013). Two new secoiridoids from Chelonanthus alatus (aubl.) pulle (gentianaceae). Bol. Latinoam. Caribe Plantas Med. Aromat.12, 186–195.

  • Google Scholar

• 109

  Sheng N. Yuan L. Zhi X. Cui C. Zhang Z. Jia P. et al (2014). Application of a liquid chromatography-tandem mass spectrometry method to the pharmacokinetics, tissue distribution and excretion studies of sweroside in rats. J. Chromatogr. B969, 1–11. 10.1016/j.jchromb.2014.07.042

  • CrossRef
  • Google Scholar

• 110

  Sichaem J. Khumkratok S. Siripong P. Tip-pyang S. (2016). A new non-glucosidic iridoid from the roots of Strychnos nux-blanda. Nat. Prod. Commun.11, 709–710. 10.1177/1934578x1601100602

  • CrossRef
  • Google Scholar

• 111

  Sichaem J. Worawalai W. Tip-pyang S. (2012). Chemical constituents from the roots of Nauclea orientalis. Chem. Nat. Comp.48, 827–830. 10.1007/s10600-012-0393-z

  • CrossRef
  • Google Scholar

• 112

  Singh M. Mohan R. Mishra S. Goyal N. Shanker K. Gupta N. et al (2019). Ultra performance liquid chromatography coupled with principal component and cluster analysis of Swertia chirayita for adulteration check. J. Pharm. Biomed. Anal.164, 302–308. 10.1016/j.jpba.2018.10.054

  • CrossRef
  • Google Scholar

• 113

  Sobot A. V. Savic J. Trickovic J. F. Drakulic D. Joksic G. (2020). Toxicity assessment of Gentiana lutea L. root extract and its monoterpene compounds. Indian J. Exp. Biol.58, 609–616.

  • Google Scholar

• 114

  Sun H. Li L. Zhang A. Zhang N. Lv H. Sun W. et al (2013). Protective effects of sweroside on human MG-63 cells and rat osteoblasts. Fitoterapia84, 174–179. 10.1016/j.fitote.2012.11.010

  • CrossRef
  • Google Scholar

• 115

  Szumny D. Kucharska A. Z. Czajor K. Bernacka K. Ziólkowska S. Krzyzanowska-Berkowska P. et al (2024). Extract from Aronia melanocarpa, Lonicera caerulea, and Vaccinium myrtillus improves near visual acuity in people with presbyopia. Nutrients16, 926. 10.3390/nu16070926

  • CrossRef
  • Google Scholar

• 116

  Tan M. A. Lagamayo M. W. D. Alejandro G. J. D. An S. S. A. (2019). Anti-amyloidogenic and cyclooxygenase inhibitory activity of Guettarda speciosa. Molecules24, 4112. 10.3390/molecules24224112

  • CrossRef
  • Google Scholar

• 117

  Tan R. X. Kong L. D. (1997). Secoiridoids from Gentiana siphonantha. Phytochemistry46, 1035–1038. 10.1016/s0031-9422(97)00225-2

  • CrossRef
  • Google Scholar

• 118

  Tan R. X. Kong L. D. Wei H. X. (1998). Secoiridoid glycosides and an antifungal anthranilate derivative from Gentiana tibetica. Phytochemistry47, 1223–1226. 10.1016/s0031-9422(97)00698-5

  • CrossRef
  • Google Scholar

• 119

  Tan R. X. Wolfender J. L. Zhang L. X. Fuzzati W. Marston A. Hostettmann K. et al (1996). Acyl secoiridoids and antifungal constituents from Gentiana macrophylla. Phytochemistry42, 1305–1313. 10.1016/0031-9422(96)00149-5

  • CrossRef
  • Google Scholar

• 120

  Tang X.-Y. Dai Z.-Q. Shi D.-F. Zeng J.-X. Wang X.-L. Li L. et al (2021). An UHPLC-MS/MS method for simultaneous determination of ten sex steroid hormones in ovariectomy-induced osteoporosis rat and its application in discovery of sex steroid hormones regulatory components of xian-ling-gu-bao capsule. J. Pharm. Biomed. Anal.195, 113888. 10.1016/j.jpba.2020.113888

  • CrossRef
  • Google Scholar

• 121

  Tao Y. Huang S. R. Li W. D. Cai B. C. (2019). Simultaneous determination of ten bioactive components in raw and processed Radix dipsaci by UPLC-Q-TOF-MS. J. Chromatogr. Sci.57, 122–129. 10.1093/chromsci/bmy093

  • CrossRef
  • Google Scholar

• 122

  Tao Y. Ren Y. C. Li W. D. Cai B. C. Di L. Q. Shi L. Y. et al (2016). Comparative pharmacokinetic analysis of extracts of crude and wine-processed Dipsacus asper in rats by a sensitive ultra-performance liquid chromatography-tandem mass spectrometry approach. J. Chromatogr. B1036, 33–41. 10.1016/j.jchromb.2016.09.024

  • CrossRef
  • Google Scholar

• 123

  Tatuedom O. K. Kouam S. F. Yapna D. B. Ngadjui B. T. Green I. R. Choudhary M. I. et al (2014). Spiroalkaloids and coumarins from the stem bark of Pauridiantha callicarpoides. Z. Naturforsch. B69, 747–752. 10.5560/znb.2014-4055

  • CrossRef
  • Google Scholar

• 124

  Tian X. Y. Wang Y. H. Liu F. Y. Yu S. S. Fang W. S. (2007). On the chemical constituents of Dipsacus asper. Chem. Pharm. Bull.55, 1677–1681. 10.1248/cpb.55.1677

  • CrossRef
  • Google Scholar

• 125

  Tomassini L. Ventrone A. Frezza C. Foddai S. Serafini M. (2020). Iridoids and seco-iridoids from the leaves of Cephalanthus glabratus (spreng.). K. Schum. Braz. J. Bot.43, 685–688. 10.1007/s40415-020-00667-8

  • CrossRef
  • Google Scholar

• 126

  Tong L. Yue L. Li T. (2015). Medicinal ethnic botany research of Swertia genus. Nat. Prod. Res. Dev.27, 191. 10.16333/j.1001-6880.2015.01.038

  • CrossRef
  • Google Scholar

• 127

  Tovilovic-Kovacevic G. Zogovic N. Krstic-Milosevic D. (2020). Chapter 19—Secondary metabolites from endangered gentiana, gentianella, centaurium, and swertia species (gentianaceae): promising natural biotherapeutics. Biodivers. Biomed. 335–384, 335–384. 10.1016/b978-0-12-819541-3.00019-0

  • CrossRef
  • Google Scholar

• 128

  Wang B. Jiang H. M. Qi L. M. Li X. Huang Q. Xie X. et al (2024a). Deciphering resveratrol's role in modulating pathological pain: from molecular mechanisms to clinical relevance. Phytother. Res.38, 59–73. 10.1002/ptr.8021

  • CrossRef
  • Google Scholar

• 129

  Wang C. Z. Maier U. H. Eisenreich W. Adam P. Obersteiner I. Keil M. et al (2001). Unexpected biosynthetic precursors of Amarogentin—A retrobiosynthetic 13C NMR study. Eur. J. Org. Chem.2001, 1459–1465. 10.1002/1099-0690(200104)2001:8<1459::aid-ejoc1459>3.0.co;2-0

  • CrossRef
  • Google Scholar

• 130

  Wang D. Yu X. Gao K. Li F. H. Li X. Pu H. Y. et al (2024b). Sweroside alleviates pressure overload-induced heart failure through targeting CaMKⅡδ to inhibit ROS-Mediated NF-κB/NLRP3 in cardiomyocytes. Redox Biol.74, 103223. 10.1016/j.redox.2024.103223

  • CrossRef
  • Google Scholar

• 131

  Wang J. Cai X. L. Ma R. Lei D. P. Pan X. L. Wang F. S. (2021). Anti-inflammatory effects of sweroside on LPS-induced ALI in mice via activating SIRT1. Inflammation44, 1961–1968. 10.1007/s10753-021-01473-4

  • CrossRef
  • Google Scholar

• 132

  Wang J. H. Ma X. C. Si X. P. Han W. (2023). Sweroside functionalized with mesenchymal stem cells derived exosomes attenuates sepsis-induced myocardial injury by modulating oxidative stress and apoptosis in rats. J. Biomater. Appl.38, 381–391. 10.1177/08853282231194317

  • CrossRef
  • Google Scholar

• 133

  Wang M. Zheng X. Yang M. Ni J. Xiao Q. Han H. et al (2024c). Iridoid for drug discovery: structural modifications and bioactivity studies. Med. Chem. Res.33, 2329–2346. 10.1007/s00044-024-03311-2

  • CrossRef
  • Google Scholar

• 134

  Wang R. Dong Z. Y. Lan X. Z. Liao Z. H. Chen M. (2019). Sweroside alleviated LPS-Induced inflammation via SIRT1 mediating NF-κB and FOXO1 signaling pathways in RAW264.7 cells. Molecules24, 872. 10.3390/molecules24050872

  • CrossRef
  • Google Scholar

• 135

  Wang W. X. Tan Y. Mao J. X. Xiong W. (2024d). Swertiamarin and sweroside are potential inhibitors of COVID-19 based on the silico analysis. Medicine103, e40425. 10.1097/md.0000000000040425

  • CrossRef
  • Google Scholar

• 136

  Wang Y. L. Xiao Z. Q. Liu S. Wan L. S. Yue Y. D. Zhang Y. T. et al (2013). Antidiabetic effects of Swertia macrosperma extracts in diabetic rats. J. Ethnopharmacol.150, 536–544. 10.1016/j.jep.2013.08.053

  • CrossRef
  • Google Scholar

• 137

  Wani B. A. Ramamoorthy D. Rather M. A. Arumugam N. Qazi A. K. Majeed R. et al (2013). Induction of apoptosis in human pancreatic MiaPaCa-2 cells through the loss of mitochondrial membrane potential (Δψm) by Gentiana kurroo root extract and LC-ESI-MS analysis of its principal constituents. Phytomedicine20, 723–733. 10.1016/j.phymed.2013.01.011

  • CrossRef
  • Google Scholar

• 138

  Wei L. (2021). Study on efficacy and mechanism of sweroside from Pterocephalus hookeri to ameliorate bone destruction in rheumatoid arthritis (Master's dissertation). Chongqing, China: Southwest University.

  • Google Scholar

• 139

  Wei S. Chen G. He W. Chi H. Abe H. Yamashita K. et al (2012). Inhibitory effects of secoiridoids from the roots of Gentiana straminea on stimulus-induced superoxide generation, phosphorylation and translocation of cytosolic compounds to plasma membrane in human neutrophils. Phytother. Res.26, 168–173. 10.1002/ptr.3496

  • CrossRef
  • Google Scholar

• 140

  Win N. N. Kodama T. Lae K. Z. W. Win Y. Y. Ngwe H. Abe I. et al (2019). Bis-iridoid and iridoid glycosides: viral protein R inhibitors from Picrorhiza kurroa collected in Myanmar. Fitoterapia134, 101–107. 10.1016/j.fitote.2019.02.016

  • CrossRef
  • Google Scholar

• 141

  Wolfender J. L. Hamburger M. Hostettmann K. Msonthi J. D. Mavi S. (1993). Search for bitter principles in chironia species by LC-MS and isolation of a new secoiridoid diglycoside from Chironia krebsii. J. Nat. Prod.56, 682–689. 10.1021/np50095a004

  • CrossRef
  • Google Scholar

• 142

  Won Y. M. Seong Z. K. Kim J. L. Kim H. S. Song H. H. Kim D. Y. et al (2015). Triterpene glycosides with stimulatory activity on melanogenesis from the aerial parts of Weigela subsessilis. Arch. Pharm. Res.38, 1541–1551. 10.1007/s12272-014-0524-0

  • CrossRef
  • Google Scholar

• 143

  Woo S. Y. Win N. N. Oo W. M. N. Ngwe H. Ito T. Abe I. et al (2019). Viral protein R inhibitors from Swertia chirata of Myanmar. J. Biosci. Bioeng.128, 445–449. 10.1016/j.jbiosc.2019.04.006

  • CrossRef
  • Google Scholar

• 144

  Wu C. Wei Y. Ge S. Gao H. Q. (2021). Effect of swertiamarin, gentiopicrin and sweroside on cell apoptosis and expression of Bcl-2 in rheumatoid arthritis fibroblast-like synoviocytes. Zhongguo Zhong Yao Za Zhi46, 406–411. 10.19540/j.cnki.cjcmm.20200927.401

  • CrossRef
  • Google Scholar

• 145

  Wu M. Wu P. Liu M. F. Xie H. H. Jiang Y. M. Wei X. Y. (2009). Iridoids from Gentiana loureirii. Phytochemistry70, 746–750. 10.1016/j.phytochem.2009.03.018

  • CrossRef
  • Google Scholar

• 146

  Wu P. Chang C. Zhu G. Zhai L. Zhang X. Huan Q. et al (2023). Network pharmacology study of bioactive components and molecular mechanisms of the glycoside fraction from Picrorhiza scrophulariiflora against experimental colitis. Drug Des. Dev. Ther.17, 1531–1546. 10.2147/dddt.S407339

  • CrossRef
  • Google Scholar

• 147

  Wu Q. C. Tang X. Y. Dai Z. Q. Dai Y. Xiao H. H. Yao X. S. (2020). Sweroside promotes osteoblastic differentiation and mineralization via interaction of membrane estrogen receptor-α and GPR30 mediated p38 signalling pathway on MC3T3-E1 cells. Phytomedicine68, 153146. 10.1016/j.phymed.2019.153146

  • CrossRef
  • Google Scholar

• 148

  Wu W. S. Ye H. Y. Tang M. H. Peng A. H. Shi J. Li S. C. et al (2012). Using high-performance counter-current chromatography combined with preparative high-performance liquid chromatography for the separation of bioactive compounds from the water extract of Gentiana macrophylla pall. Sep. Sci. Technol.47, 762–768. 10.1080/01496395.2011.621920

  • CrossRef
  • Google Scholar

• 149

  Xu R. J. Yu B. M. Wang S. Q. Wei X. Zhou P. Yuan Y. C. (2020). Intestinal absorption mechanism and the effect of Cornus officinalis sieb. Zucc. Sweroside vitro vivo. Lat. Am. J. Pharm.39, 1500–1508.

  • Google Scholar

• 150

  Yang C. C. Zheng C. C. Luo Y. Guo K. W. Gao D. Zhang L. et al (2022). Cornel iridoid glycoside and its effective component regulate ATPase Vps4A/JNK to alleviate autophagy deficit with autophagosome accumulation. Am. J. Chin. Med.50, 1599–1615. 10.1142/s0192415x22500677

  • CrossRef
  • Google Scholar

• 151

  Yang C. J. Zhang N. Wu S. X. Jiang C. Y. Xie L. Yang F. et al (2023). A comparative analysis of the chloroplast genomes of three lonicera medicinal plants. Genes14, 548. 10.3390/genes14030548

  • CrossRef
  • Google Scholar

• 152

  Yang G. Jang J. H. Kim S. W. Han S. H. Ma K. H. Jang J. K. et al (2020a). Sweroside prevents non-alcoholic steatohepatitis by suppressing activation of the NLRP3 inflammasome. Int. J. Mol. Sci.21, 2790. 10.3390/ijms21082790

  • CrossRef
  • Google Scholar

• 153

  Yang J. Zhu D. Ju B. Jiang X. Hu J. (2017). Hepatoprotective effects of gentianella Turkestanerum extracts on acute liver injury induced by carbon tetrachloride in mice. Am. J. Transl. Res.9, 569–579.

  • Google Scholar

• 154

  Yang Q. L. Shu F. F. Gong J. T. Ding P. Cheng R. R. Li J. M. et al (2020b). Sweroside ameliorates NAFLD in high-fat diet-induced Obese mice through the regulation of lipid metabolism and inflammatory response. J. Ethnopharmacol.255, 112556. 10.1016/j.jep.2020.112556

  • CrossRef
  • Google Scholar

• 155

  Yang Q. L. Yang F. Gong J. T. Tang X. W. Wang G. Y. Wang Z. T. et al (2016). Sweroside ameliorates α-naphthylisothiocyanate-induced cholestatic liver injury in mice by regulating bile acids and suppressing pro-inflammatory responses. Acta Pharmacol. Sin.37, 1218–1228. 10.1038/aps.2016.86

  • CrossRef
  • Google Scholar

• 156

  Yao C. Y. Song Z. J. Ruan L. J. Yan B. X. Wu Q. H. He L. L. et al (2021). A new methoxylated flavone from Lonicera hypoglauca and its chemotaxonomic significance. Biochem. Syst. Ecol.97, 104279. 10.1016/j.bse.2021.104279

  • CrossRef
  • Google Scholar

• 157

  Yin Y. Y. Fu H. H. Mi F. K. Yang Y. Wang Y. M. Li Z. et al (2024). Genomic characterization of WRKY transcription factors related to secoiridoid biosynthesis in Gentiana macrophylla. BMC Plant Biol.24, 66. 10.1186/s12870-024-04727-z

  • CrossRef
  • Google Scholar

• 158

  Zengin G. El-Raey M. El-Kashak W. Batiha G. E. Althumairy D. Alamer S. et al (2023). Sweroside: an iridoid glycoside of potential neuroprotective, antidiabetic, and antioxidant activities supported by molecular docking. Amino Acids55, 1765–1774. 10.1007/s00726-023-03262-9

  • CrossRef
  • Google Scholar

• 159

  Zhang J. Zhang Z. X. Wang Y. Z. Zuo Y. M. Cai C. T. (2020). Environmental impact on the variability in quality of Gentiana rigescens, a medicinal plant in southwest China. Glob. Ecol. Conserv.24, e01374. 10.1016/j.gecco.2020.e01374

  • CrossRef
  • Google Scholar

• 160

  Zhang L. Ulriksen E. S. Hoel H. Sandvik L. Malterud K. E. Inngjerdingen K. T. et al (2023). Phytochemical characterization and anti-inflammatory activity of a water extract of Gentiana purpurea roots. J. Ethnopharmacol.301, 115818. 10.1016/j.jep.2022.115818

  • CrossRef
  • Google Scholar

• 161

  Zhang R. Wang C. M. Jiang H. J. Tian X. G. Li W. J. Liang W. et al (2019). Protective effects of sweroside on IL-1-induced inflammation in rat articular chondrocytes through suppression of NF-κB and mTORC1 signaling pathway. Inflammation42, 496–505. 10.1007/s10753-018-0906-4

  • CrossRef
  • Google Scholar

• 162

  Zhang X. R. Yu X. Sun X. M. Meng X. B. Fan J. Zhang F. et al (2024). Comparative study on chemical constituents of different medicinal parts of Lonicera japonica thunb. Based on LC-MS combined with multivariate statistical analysis. Heliyon10, e31722. 10.1016/j.heliyon.2024.e31722

  • CrossRef
  • Google Scholar

• 163

  Zhang Y. D. Huang X. Zhao F. L. Tang Y. L. Yin L. (2015). Study on the chemical markers of caulis Lonicerae japonicae for quality control by HPLC-QTOF/MS/MS and chromatographic fingerprints combined with chemometrics methods. Anal. Methods7, 2064–2076. 10.1039/c4ay02744b

  • CrossRef
  • Google Scholar

• 164

  Zheng M. Karki R. Vogel P. Kanneganti T. D. (2020). Caspase-6 is a key regulator of innate immunity, inflammasome activation, and host defense. Cell181, 674–687.e13. 10.1016/j.cell.2020.03.040

  • CrossRef
  • Google Scholar

• 165

  Zhou D. Lv D. Zhang H. Cheng T. Wang H. Lin P. et al (2021a). Quantitative analysis of the profiles of twelve major compounds in Gentiana straminea maxim. Roots by LC-MS/MS in an extensive germplasm survey in the Qinghai-Tibetan plateau. J. Ethnopharmacol.280, 114068. 10.1016/j.jep.2021.114068

  • CrossRef
  • Google Scholar

• 166

  Zhou M. Y. Xie Z. R. Guan W. W. Zhang J. Q. (2021b). Comparative analysis of bioactive constituents and pharmacological activities from different parts of Nauclea officinalis. Biomed. Chromatogr.35, e5214. 10.1002/bmc.5214

  • CrossRef
  • Google Scholar

• 167

  Zhu K. C. Ma C. H. Ye G. Fan M. S. Huang C. G. (2007). Two new secoiridoid glycosides from Tripterospermum chinense. Helv. Chim. Acta90, 291–296. 10.1002/hlca.200790033

  • CrossRef
  • Google Scholar